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Abstract of the Dissertation
The Processing of Amyloid Precursor Protein in the
Central Nervous System of Humans and Rhesus Macaques
by
Justyna Anna Dobrowolska
Doctor of Philosophy in Neurosciences
Washington University in St. Louis, 2013
Professor Randall J. Bateman, Chair

Alzheimer’s disease (AD) is the most common dementia, currently afflicting 30 million people
worldwide, with prevalence steadily increasing. Over 99% of AD cases are classified as
sporadic, in which the major risk factors are age (greater than 65 years) and the ApoE-ε4 allele
(in a gene dose dependent manner). The minority of AD cases (less than 1%) are caused by
autosomal dominant inheritance of a genetic mutation in one of three genes: Amyloid Precursor
Protein (APP), Presenilin-1 (PSEN1), or Presenilin-2 (PSEN2). Mutation carriers will generally
notice cognitive decline starting at a relatively young age, anytime between their 30s-50s, and
eventually succumb to this early-onset AD. Early-onset AD may also be the result of an extra
copy of the APP gene, as manifested in Down Syndrome (DS) patients, who universally develop
AD.
Alzheimer’s disease pathophysiology appears to revolve around APP. This transmembrane
protein may be processed through one of two pathways. If APP is processed down the
amyloidogenic (β-secretase) pathway, soluble APPβ (sAPPβ) will be released first, and with a
subsequent cleavage, β-amyloid (Aβ), will be released into the brain where it could sequester

xiv

into amyloid plaques, which are a major hallmark of AD. The other processing pathway is
caused by cleavage of APP by α-secretase. This results in the release of soluble APPα (sAPPα),
which precludes the release of Aβ, thus making this pathway non-amyloidogenic.
Several studies have focused on measuring the products of APP cleavages in an effort to
elucidate the pathophysiology of AD. These studies give a static view of APP because they
measure absolute amounts of protein in single samples. However, proteins are constantly being
produced, cleared, and aggregated which may result in protein concentrations fluctuating over
time. Recently it was reported that Aβ exhibits a diurnal pattern, the definitive cause of which is
still unknown.
The general goal of this thesis is to determine the interplay of the α- and β-secretase APP
processing pathways in both physiological and pathophysiological settings in humans, to
establish the human metabolism rates of total sAPP, sAPPα, and sAPPβ, and to determine
whether drug intervention of one of the two APP pathways, would have an effect the other
pathway. The aims of this thesis are:
1)

To determine the extent of interdependence of the α-secretase and the β-secretase APP

processing pathways in humans and whether Aβ diurnal patterns were being driven by APP.
Human cerebrospinal fluid (CSF) was collected hourly for 36 h, and concentrations of sAPPα,
sAPPβ, Aβ40, and Aβ42 were measured by four metabolite-specific ELISAs. Parameters
associated with diurnal patterns were compared among metabolites. Further, correlation
analyses were used to determine if any correlation among metabolites at a single time-point was
evident. Samples from Alzheimer’s patients, age-matched controls, and young healthy controls
were analyzed.

xv

2)

To determine the physiological and pathophysiological metabolism of sAPPα and sAPPβ

in humans. Total sAPP was isolated by immunoprecipitation from CSF of participants
undergoing stable isotope labeling kinetics studies. Isolated sAPP underwent proteolytic
cleavage by trypsin and turnover rates of total sAPP were determined by LC-MS and compared
to turnover rates of Aβ. Isolated total sAPP that underwent proteolytic cleavage by Arginine-C
produced some preliminary results that could lead to eventual determination of sAPPα or sAPPβ
specific turnover rates in humans.
3)

To determine the physiological metabolism of sAPPα and sAPPβ in rhesus macaques in

comparison to Aβ metabolism and to determine if drug intervention of the β-secretase pathway
by a BACE1 inhibitor would affect the α-secretase pathway. Soluble APPβ, sAPPα and Aβ were
isolated from rhesus macaque CSF by serial immunoprecipitation. Monkeys were undergoing
stable isotope labeling kinetics studies. Isolated APP metabolites underwent proteolytic cleavage
by LysN, and then the turnover rates of these metabolites were measured by LC-MS to determine
if the BACE1 inhibitor was hitting its target, and if it was having any effect of the α-secretase
pathway.
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Chapter 1 Introduction and Perspective
Alzheimer’s Disease as a Major Public Health Issue
Alzheimer’s Disease (AD) is a progressive, debilitating neurological disease that manifests itself
th

with symptoms of memory deficits and problems with thinking and behavior. It is the 6 leading
cause of death in the U.S.A. There is no effective preventative treatment, and no medical
intervention that will slow disease progression, halt it, or otherwise reverse its symptoms.
Therefore, AD is universally fatal. Of the leading causes of death in the U.S.A., only AD cases
have been on the rise. In the first decade of the 2000s, AD prevalence increased by 68%. It is
estimated that this year (2013) there are 5.2 million Americans afflicted with this disease, of
which approximately five million are over the age of 65. The U.S.A. is facing the stark reality of
a further rapid increase in AD diagnoses as the eldest of those born during the Post World War II
baby boom are now nearing 70 years of age. Estimates indicate that by the year 2025, the
prevalence of AD in people 65 years and older will reach 7.1 million. The direct cost of care for
all AD patients in the USA in 2013 is predicted to be $203 billion, and, unless new medical
breakthroughs become available, the costs will increase exponentially to an estimated $1.2
trillion per year by 2050 (Alzheimer’s Association, 2013). All this taken together indicates that
AD is clearly a major public health issue, and efforts to understand better AD pathophysiology,
as well as discover effective drug interventions need to be a priority.

1

The Amyloid Hypothesis
In 1906, at a medical conference, a psychiatrist, Alois Alzheimer, first discussed his findings of a
clinicopathological disorder that later was named in his honor. Dr. Alzheimer’s description was
based on the analysis of a female patient named Auguste D., who manifested early-onset AD,
dying at the age of 56 years (Alzheimer, 1907). He documented her cognitive deficits, along
with describing two pathological hallmarks of this disease by studying Auguste D.’s brain after
death. The two classic brain lesions that Alzheimer’s described are still considered the hallmarks
of AD: the extracellular neuritic plaques composed of Amyloid-β, Aβ (predominantly Aβ42), and
the intracellular neurofibrillary tangles composed of hyperphosphorylated tau proteins.
However, the molecular pathophysiology of AD is still not fully understood, and decades of
biomedical research have helped to formulate the Amyloid Hypothesis (Hardy and Selkoe,
2002). The evidence supporting this hypothesis centers on Aβ and its precursor, Amyloid
Precursor Protein (APP), as key proteins implicated in AD pathophysiology. Additional data
that corroborate this hypothesis include but are not limited to the list herein:
Cognitively normal participants with low Aβ42 CSF concentrations are those that, when followed
longitudinally, tend to develop AD (Skoog et al., 2003; Gustafson et al., 2007; Stomrud et al.,
2007). There are three genes (APP, Presenilin-1 (PSEN1), and Presenilin-2 (PSEN2)) known to
have a number of potential mutations (50+, 150+, and 10+, respectively) that have been shown to
increase Aβ production and/or aggregation. Carriers of these mutations universally develop
autosomal-dominant AD (ADAD) (Bateman et al., 2011). Recent studies indicated that the
biomarker, clinical, and cognitive presentation of ADAD was remarkably similar to the later
onset sporadic AD (Bateman et al., 2012). The first ADAD mutation discovered was a missense
mutation in APP which increased the production of Aβ42, a longer form of Aβ more prone to
2

aggregate (Goate et al., 1991). The discovery of mutations that cause AD revolutionized the
molecular biology studies of AD by providing definitive evidence that alterations in APP, likely
through Aβ processing, was sufficient to cause AD. Subsequent mutations were found in PSEN1
(Sherrington et al., 1995), and PSEN2 (Levy-Lahad et al., 1995). Interestingly, Auguste D., the
first patient described by Dr. Alzheimer, had a PSEN1 mutation as the likely cause of her
dementia (Müller et al., 2013).
Recently, Jonsson et al. (2012) characterized a coding mutation on the APP gene in an Icelandic
population. This mutation appeared to protect the elderly non-AD human participants from
cognitive decline. The mutation, A673T, was found to decrease Aβ in both cell culture assays
and animal models.
Conclusions from the study of Down Syndrome (DS) patients, who universally develop classic
AD pathology by 35 years of age (Malamud 1972; Wisniewski et al., 1985), were consistent with
the Amyloid Hypothesis. Patients with DS are born with an extra copy of chromosome 21
(Hassold et al., 1993), which is the chromosome on which the gene encoding APP is located.
Down Syndrome patients have 50% more total APP than their healthy human counterparts.
Those with DS have been shown to overproduce APP and Aβ and have amyloid plaques present
in the brain as early as 12 years of age. These plaques precede other pathological hallmarks of
AD, such as neurofibrillary tangles (Lemere et al., 1996; Querfurth et al., 1995).
The type 4 allele of the apolipoprotein E gene, ApoE-ε4, is the most common genetic risk factor
for sporadic AD and has been shown to alter Aβ deposition. In a gene dose dependent manner,
ApoE-ε4 increases both the amount of fibrillar amyloid deposition in the brain (Morris et al.,
2010) and the probability of developing late-onset AD (Corder et al., 1993).

3

Amyloid Precursor Protein Expression
Amyloid Precursor Protein is a ubiquitous transmembrane protein that ranges between 110 and
140 kDa when measured by electrophoresis (Selkoe et al, 1982). The differences in protein size
may be attributed to several factors, such as several potential splice variants and posttranslational modifications. APP has three major isoforms that are 695, 751, or 770 amino acid
residues in length. Neuronal cells predominantly express APP695, and this splice variant is found
in non-neuronal tissue to a very low degree (Haass et al., 1991). Both APP751 and APP770 do
occur in neurons but to a lesser extent than APP695. These two longer APP variants are widely
expressed in non-neuronal tissue. APP695 lacks an exon coding for the 56 amino acid sequence
homologous to the so-called Kunitz-type of serine protease inhibitors (KPI). Post-translational
modifications of APP include N- and O-linked sugar additions and sulfation or phosphorylation
(Hung and Selkoe, 1994; Oltersdorf et al, 1990; Walter et al., 1997; Weidemann et al., 1989).

Amyloid Precursor Protein Localization
Amyloid Precursor Protein is localized in the membranes of the cell, the endoplasmic reticulum
(ER), Golgi apparatus, and endosomes (Koo et al., 1996; Yamazaki et al., 1996; Skovronsky et
al., 2000). The N-terminus of APP is situated on the exterior of the cell or the interior of an
organelle membrane. Amyloid Precursor Protein is cotranslationally translocated into the ER,
and later it becomes mature after posttranslational modifications occurring in the secretory
pathway (here APP obtains the N- and O- sugars mentioned in the previous section). During and
after trafficking through the secretory pathway, APP may undergo post-translational processing
through one of two pathways: the α-secretase (non-amyloidogenic) pathway and the β-secretase
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(amyloidogenic) pathway (Figure 1.1., Table 1.1.). The relationship between these two
processing pathways of APP in the human CNS is not fully understood.

Proteolytic Processing of Amyloid Precursor Protein

Figure 1.1. Proteolytic processing of Amyloid Precursor Protein. Amyloid Precursor
Protein may be processed through the non-amyloidogenic (α-secretase) pathway or the
amyloidogenic (β-secretase) pathway.

It is through the amyloidogenic pathway that APP can be processed in two steps to result in the
production of Aβ. In the first step, APP is cleaved by β-secretase (the major neuronal βsecretase is β-site APP-cleaving enzyme 1, or BACE1) in the ectodomain (C-terminal to amino
acid 671). The soluble fragment resulting from this cleavage is the 671 amino acid sAPPβ.
Owing to this cleavage, the remaining APP ectodomain (C-terminal Fragment (CTF) 99) now
5

contains the first amino acid sequence of Aβ as its N-terminus. It is then available to be
subsequently cleaved in the endodomain by γ-secretase. The result of this cleavage is the release
of Aβ into the intracellular compartment’s lumen or into the extracellular fluid (ECF) (Busciglio
et al., 1993) while the APP fragment that remains in the membrane is the APP Intracellular
Domain (AICD). The processing of APP through the β-secretase pathway occurs predominantly
in endosomes, where the acidic environment is favorable for BACE activity. γ-secretase also
becomes very active in the late endosomes. Therefore, sAPPβ and Aβ are released into the ECF
when either early endosomes are recycled to the cell surface or when late endosomes fuse with
the cell membrane. Conversely late endosomes may fuse with lysosomes and the sAPPβ and Aβ
will be degraded.
During the processing through the non-amyloidogenic pathway, APP first undergoes cleavage by
α-secretase, producing a soluble product known as sAPPα and the remaining APP
transmembrane CTF 83. Cleavage at this site precludes the formation and release of Aβ because
this site is located between the 16th and 17th amino acids of Aβ. Therefore, when γ-secretase
subsequently cleaves the APP endodomain, the resulting soluble fragment, p3, is missing the first
16 amino acids that are included in the Aβ sequence. As in the amyloidogenic pathway, AICD is
the APP fragment remaining in the membrane. The p3 fragment has not been reported to self
aggregate as does Aβ. In addition to preventing the release of Aβ, some evidence indicates that
this pathway may be neuroprotective in its own right. The C-terminus of sAPPα has been shown
to protect neurons against glutamate-induced toxicity, glucose deprivation, and Aβ toxicity,
among others (Furukawa et al., 1996; Goodman et al., 1994; Smith-Swintosky et al., 1994).
Furthermore, some studies have demonstrated sAPPα’s connection to improved memory in
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rodents. Processing of APP through the α-secretase pathway occurs predominantly at the cell
surface (Parvathy et al., 1999) thus sAPPα is mainly released directly into the ECF.
The α- and β- APP processing pathways may be completely independent of one other, in which
case an increase or decrease of APP processing through one pathway would have no effect on the
other pathway. However, it is possible that the two pathways are interrelated to some extent.
For example, if there is an increase in APP processing through the α-pathway, there will be a
proportional decrease in the amount of APP processed through the β-pathway. It is essential to
know how the two pathways relate to one another because this will help inform drug
development efforts as to the related effects of decreasing Aβ on increasing the α-secretase
pathway. In addition, knowledge of the basic physiology of these secretase systems in the
human CNS is important to understand the pathophysiology of AD and may provide insight into
the function of the APP in the CNS.

Table 1.1. Amyloid Precursor Protein proteolytic products and secretases required for
cleavages.
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Trafficking of Amyloid Precursor Protein
The trafficking of APP is not straight forward. The translated APP may be trafficked from the
ER to the cell membrane in the secretory pathway or it may be trafficked to the Golgi and then to
late endosomes or lysosomes. When APP reaches the cell membrane, if it is uncleaved by α- and
γ-secretases (both active at this location), it may be reinternalized into early endosomes where it
may be cleaved sequentially by β- and γ-secretases. There is much evidence that the β-secretase
processing pathway of APP occurs in the endocytic pathway. Endocytosis of APP appears to be
necessary for Aβ production. Its production is decreased, while sAPPα and cell surface APP
increases, when endocytosis is experimentally inhibited by several different methods (Koo and
Squazzo, 1994). As mentioned above, BACE is localized to cellular compartments that have an
acidic pH (Yu et al., 2000; Haass et al., 1995). The γ-secretase complex, which is responsible
for the final cleavage of APP that releases Aβ, has also been reported to be not only localized at
the cell surface, but also throughout intracellular compartments, such as the ER, TGN,
endosomes, and lysosomes (Ray et al., 1999; Pasternak et al., 2003; Cupers et al., 2001). Taken
together, it is not surprising that Aβ secretion is increased in the endocytic pathway. Aβ may be
released into the ECF through recycling endosomes merging with the cell membrane or it may
travel further down the endocytic pathway to the late endosomes where its fate is either release
into the ECF or degradation if the late endosome fuses with a lysosome. Amyloid Precursor
Protein may also remain uncleaved by α- or β-secretase throughout its trafficking. In this case, it
will be degraded in the lysosome as an intact protein, without forming any APP metabolites.
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Diurnal patterns of Amyloid-β
The first temporal studies of Aβ concentrations in humans were reported in 2007, indicating that
CSF concentrations of Aβ40 and Aβ42 were sinusoidal over 24 h in younger healthy participants
(Bateman et al., 2007), suggesting a potentially circadian pattern (Figure 1.2.).

Figure 1.2. Diurnal fluctuations of Aβ observed in humans (Bateman et al., 2007)

Subsequent studies in humans and animal models (Kang et al., 2009) demonstrated that diurnal
rhythms of Aβ concentrations in the brain were affected by disruptions of both the sleep-wake
cycle and the signaling of orexin, a neuropeptide that regulates several physiological functions,
including wakefulness (Sakurai 2007). Recently our group reported that Aβ exhibits a diurnal
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pattern in both CSF (Huang et al., 2012a) and blood (Huang et al., 2012b) in healthy human
adults, whereas the levels of total proteins do not exhibit any significant circadian pattern. The
Aβ diurnal patterns measured, as determined by circadian amplitude, were decreased with aging
and amyloidosis. This decrease coincided with observed disturbances in sleep with age (Redline
et al., 2004) and neurodegeneration (Gagnon et al., 2008), and therefore may be ultimately linked
to the sleep-wake cycle and orexin signaling. However, the immediate mechanism for diurnal
regulation of Aβ has not been described, and possible causes for the Aβ diurnal pattern include
diurnal regulation of APP transcription, translation, or transport, or diurnal regulation affecting
the two secretases (β-secretase or γ-secretase) that cleave APP to produce Aβ.

Elevated β-secretase in AD
Elevated BACE1 expression and activity have been reported in post-mortem human AD brains.
In living human participants, BACE1 activity in the CSF positively correlates with fibrillar
amyloid pathology, as measured by carbon-11-labeled Pittsburgh Compound B positron
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emission tomography ([ C] PIB PET) (Grimmer et al., 2012). Some results indicate that BACE
activity was slightly higher in CSF of AD participants than in controls (Fukumoto et al., 2002;
Johnston et al., 2005; Holsinger et al., 2006; Holsinger et al., 2004; Verheijen et al., 2006). In
another study, participants with Mild Cognitive Impairment (MCI) had both higher BACE
activity and protein levels (Zhong et al., 2007). Another group (Zetterberg et al., 2008)
demonstrated that sAPPα and sAPPβ were highly positively correlated in MCI and AD
participants. They also showed that, except in the MCI group that progressed to AD, BACE1
activity positively correlated with sAPPα, sAPPβ, and Aβ40. Owing to the elevated β-secretase
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activity, APP processing may be directly affected in AD to the amyloidogenic pathway, thus
making BACE inhibitors attractive therapeutics for this disease.

In vivo Stable Isotope Labeling and the LC/MS approach
In most cases, absolute amounts or concentrations of proteins can be detected by different
methods available to researchers using standard curves (e.g. Western Blot, ELISA,
immunoassays). Absolute protein amounts and concentrations are the result of the protein’s
metabolism (production and clearance rates). However, protein quantitation does not inform
about the protein’s kinetics or metabolism. To determine why the changes of protein level are
occurring, protein kinetics need to be measured. Is it because there is an overproduction or
underproduction of a protein? Is the protein being cleared too slowly or too quickly? Or is it a
combination of the two factors? In vivo stable isotope labeling has been utilized to address these
questions in other systems. The administration of a stable-isotope labeled amino acid into an in
vitro or in vivo system provides a method to label proteins that are being produced at a specific
time and track the newly produced proteins kinetics including production and clearance. By
measuring the ratio of labeled to unlabeled proteins the assessment of production and clearance
rates of a specified protein can be made. Mass spectrometry can be utilized to quantify isotope
labeled and unlabeled peptides and proteins. By measuring labeled proteins over time during
and after labeling, kinetic curves can be obtained and used for calculation of kinetic parameters
and model fits. The kinetic measurements then inform about the rates of processing, thus adding
the time dimension to analysis of protein physiology.
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Chapter 2 Diurnal Regulation of Amyloid Precursor
Protein in Humans
Introduction
Although the pathophysiology of AD is incompletely understood, the study of brain and
cerebrospinal fluid (CSF) proteins, such as amyloid-β (Aβ) and tau, have provided insight into
AD molecular pathophysiology (Vanderstichele et al. 1998; Galasko et al. 1998; Andreasen et al
1999; Fagan et al. 2007; Holtzman et al. 2011). The study of Aβ production, transport and
clearance is important for insight into normal brain protein handling and also for the
pathophysiology of AD.
The first human studies of Aβ concentrations over time indicated that CSF concentrations were
sinusoidal over 24 h in younger healthy participants (Bateman et al., 2007) and suggested a
possible circadian pattern. Subsequent studies in humans and animal models (Kang et al., 2009)
demonstrated Aβ concentrations in the brain could be regulated by sleep/wake cycles and orexin
administration. Recently, it was reported that Aβ exhibits a diurnal pattern in both CSF (Huang
et al., 2012a) and blood (Huang et al., 2012b) in healthy adults. The diurnal patterns, as
determined by circadian amplitude, decreased with aging and amyloidosis. The immediate
mechanism for diurnal regulation of Aβ has not been described, and possible causes for the Aβ
diurnal pattern include, but are not limited to, diurnal regulation of APP transcription,
translation, or transport, or diurnal regulation affecting the two secretases (β-secretase or γsecretase) that cleave APP to produce Aβ. In this study, we evaluated the temporal relationship
of Aβ with other proteolytic products of APP to try to determine the cause of Aβ diurnal patterns
in the CNS of healthy young and elderly humans, as well as those with amyloid pathology.
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Amyloid Precursor Protein is a single-pass transmembrane protein processed through at least two
pathways in the CNS: the β- (amyloidogenic) pathway and the α- (non-amyloidogenic) pathway
(Zheng and Koo 2011). It is cleaved in the amyloidogenic pathway by β-secretase releasing a
soluble extracellular fragment called soluble APPβ (sAPPβ). The APP endodomain, C-terminal
fragment 99 (CTF99), which remains in the transmembrane, is subsequently cleaved by gamma
(γ)-secretase, resulting in the generation of Aβ and an APP Intra-Cellular Domain. The nonamyloidogenic processing of APP occurs when α-secretase cuts APP, producing soluble APPα
(sAPPα). The endodomain of APP (CTF83) may then be cut by γ-secretase, resulting in the
release of a fragment, p3. The formation of Aβ is precluded by α-secretase cleavage.
To elucidate further the potential contributions of APP to the Aβ diurnal pattern and the balance
of the α- and β- pathways in APP processing, we measured the CSF APP proteolytic products
sAPPβ, sAPPα, and Aβ40 and Aβ42 over 36 h from cognitively normal young and elderly, plus
AD participants.

Experimental Methods and Study Design
Participants and Sample Collection.
All human studies were approved by the Washington University Human Studies Committee and
the General Clinical Research Center (GCRC) Advisory Committee. Young Normal Control
(YNC) participants were recruited from the general public. Older participants that would later be
assigned to the Amyloid- or Amyloid+ groups were recruited through the Charles F. and Joanne
Knight Alzheimer’s Disease Research Center (Knight ADRC) at Washington University.
Informed consent was obtained from all participants prior to their enrollment in the study.
Participants were in good general physical health. They had no clinical neurological diseases.
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Exclusion criteria for the study included having an active infection, a bleeding disorder, or
treatment with anticoagulants. These participants were divided into three groups by age and
brain amyloid status: 1) an Amyloid+ group of participants greater than 60 years of age and with
probable amyloid plaques in the brain, as measured by positron emission tomography using
Pittsburgh compound B (PET PiB) or determined by an Aβ42 CSF mean concentration less than
350 pg/mL; 2) an Amyloid- age-matched group that had no detectable amyloid plaques in the
brain as measured by PET PiB or determined by an Aβ42 CSF mean concentration greater than
350 pg/mL; 3) a young normal control (YNC) group (18-50 years of age) who are likely PET
PiB- (Mintun et al. 2006). PiB binds to fibrillar amyloid plaques in the brain (Klunk et al.,
2004). A mean cortical binding potential (MCBP) was calculated for each participant to
determine PiB (Amyloid) “+” or “–” status (Mintun et al. 2006). To measure the MCBP, binding
potentials of PiB were averaged from specific brain regions: prefrontal cortex, precuneus, lateral
temporal cortex, and gyrus rectus. The MCBP scores that were 0.18 or greater were designated
as amyloid plaque positive (Amyloid+), whereas those less than 0.18 were designated as amyloid
plaque negative (Amyloid-) (Mintun et al. 2006). Some participants did not have reported
MCBP values, and, in those cases, a surrogate marker of amyloid deposition was used to assign
the participant group. This surrogate marker was a low CSF Aβ42 concentration which has been
shown to be inversely correlated with PET PiB measurements (Fagan et al., 2006). A CSF Aβ42
concentration was considered low (and Amyloid+) if less than 350 pg/mL from an Aβ42 ELISA
that used 21F12 (anti-Aβ42) as the capture antibody and biotinylated 3D6 antibody (directed
against Aβ1-5) as the detection antibody.
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Demographics of Study Participants.
A total of 49 participants (both men and women) were assessed in at least one part of this study.
Specific sample size in each group varied depending on the experiment, and sample size for each
group when diurnal patterns were observed is listed in the cosinor analyses section of the
Methods. For the part of this study where APP metabolites were measured in a single CSF time
point (results shown in Figures 2.12.-2.13.) there were 15 participants in the YNC group, 15 in
Amyloid-, and 18 in Amyloid+.
The mean (SD) age for each participant group when all 49 participants were taken into account:
YNC = 37.1 (± 8.7) years; Amyloid- = 69.6 (± 4.5) years; and Amyloid+: 76.3 (±7.5) years.
Clinical Dementia Rating (CDR) at study onset was available for all participants. Of the
Amyloid- participants, 33.3% had a CDR score greater than zero (exhibited cognitive deficits).
Of the Amyloid+ participants, 29.4% had a CDR score equal to zero. All YNC subjects were
free from any cognitive deficits.
Sample Collection and Storage.
Sample collection and handling were done as previously described (Bateman et al., 2007).
Briefly, for all participants, an intrathecal lumbar catheter was placed between the L3 and L4
interspace or the L4 and L5 interspace between 7:30AM-9:00AM. Collection of CSF began
between 8:00AM and 9:30AM. Every hour for 36 h, 6 mL of CSF and 12 mL of plasma were
withdrawn. Aliquots of CSF (1 mL) were immediately frozen at -80 °C in Axygen maximumrecovery polypropylene tubes.
Sample and Standard Handling.
Aliquots (1mL) from even hours with two freeze-thaw cycles were measured by sAPPα and
sAPPβ ELISA. The effect of two freeze-thaw cycles was determined to change sAPPα (Figure
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2.1) and sAPPβ concentrations (data not shown) only marginally. Before plating, CSF samples
were diluted in phosphate buffered saline-0.05% Tween20 (PBS-T) 75- to 150-fold for sAPPα,
and 10- to 25-fold for sAPPβ. Recombinant standards from E.coli were used for both sAPPα
(Sigma S9564-25UG) and sAPPβ (S4316-25UG). The concentration of the standards ranged
from 1.6 - 75 ng/mL for sAPPα and 2.7 - 125 ng/mL for sAPPβ. Each CSF and standard sample
was assessed in triplicate.

Figure 2.1 Effect of two Freeze/Thaw cycles on CSF concentrations of sAPPα. Owing to
the CSF being accessed by multiple users, some patients’ CSF samples may have possibly
undergone one freeze-thaw cycle prior to being used in this study. Thus, to be consistent,
all samples would undergo 2 freeze-thaw cycles. To determine whether an extra
freeze/thaw cycle would decrease CSF concentrations of sAPPα, the developed ELISA was
used to test samples from the same participant, with one having undergone one freeze/thaw
cycle, and the other having undergone two cycles. As represented above, an extra
freeze/thaw cycle has no significant effect on sAPPα concentration in CSF.
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Soluble APPα ELISA Protocol.
For the sAPPα ELISAs, 96-well Nunc MaxiSorp flat bottom ELISA plates (eBiosciences, Inc.;
San Diego, CA) were coated with 100 µL per well of 5 µg/mL of 8E5 (a monoclonal antibody
raised to a bacterially expressed fusion protein corresponding to human APP444-592 of the APP770
transcript (Games et al., 1995), courtesy of Eli Lilly). Plates were incubated for 24 h on a shaker
at 4 °C, and then blocked with 3% dry milk in PBS-T for 1 h 20 min at 37 °C. To avoid plate
position effects, samples were randomly assigned to a well on the plate. Secondary (detection)
antibody (50 µL of 1:10,000 6E10-biotin (Kim et al., 1988), a monoclonal antibody reactive to
Aβ1-16, otherwise known as APP672-687 (in the APP770 transcript), and having the epitope at Aβ38,

or APP674-679) (Signet Covance; Dedham, MA) was added to each well. Samples and

secondary antibody were incubated on a shaker at 4 °C for 24 h. Plates were washed 5 times
with PBS-T and then poly-HRP20-Strepavidin (Fitzgerald Industries International; Acton, MA)
diluted at 1:15,000 in 1% bovine serum albumin (Sigma-Aldrich; St. Louis, MO) in PBS-T was
added to each well at 100µL/well. Plates were incubated in the dark for 1 h at 37 °C on a shaker.
Plates were then washed 5 times with PBS-T and 5 times with PBS. The plates were then
developed as described for the sAPPβ ELISA below.
Soluble APPβ ELISA Protocol.
For the sAPPβ ELISA, 96-well Nunc MaxiSorp flat bottom ELISA plates (eBiosciences, Inc.;
San Diego, CA) were coated with 100 µL per well of 10 µg/mL of the monoclonal antibody,
8E5. Plates were incubated for 24 h on a shaker at 4 °C, and subsequently blocked with 3% dry
milk in PBS-T for 1 h 20 min at 37 °C. Samples were randomly assigned a plate-well position
and incubated for 24 h on a shaker at 4 °C. They were then washed 5 times with PBS-T. A
biotinylated antibody against the neo-epitope (amino acid sequence: KM) of sAPPβ (courtesy of
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Eli Lilly) was used as the secondary (detection) antibody at a volume of 50 µL and a
concentration of 0.5 µg/µL, diluted in 37 °C PBS-T. The sAPPβ-biotin detection antibody was
added to each well and incubated at 37 °C for 1.5 h. Plates were washed 10 times with PBS-T
and 100 µL poly-HRP40-Strepavidin (Fitzgerald Industries International; Acton, MA), diluted at
1:20,000 in 1% bovine serum albumin in PBS-T, was added to each well. Plates were incubated
in the dark for 1 h at 25 °C on a shaker and washed 5 times with PBS-T and 5 times with PBS.
For both the sAPPα and sAPPβ ELISAs, 100 μL per well of ELISA TMB Super Slow (SigmaAldrich; St. Louis, MO), pre-warmed to 25 °C, was then added to each well. Optical density
(OD) was measured at 650 nm by using a Biotek Synergy 2 plate reader.
Amyloid-β40 and Aβ42 ELISA Protocols.
Corning 96-well half area clear flat bottom polystyrene high bind ELISA plates (Corning Life
Sciences, Tewksbury, MA) were coated with 1.25 µg/mL HJ7.4 (Aβ37-42) or 2.5 µg/mL HJ2
(Aβ33-40) in PBS plus 20% glycerol (PBS-G), then incubated 1 h at 25 °C followed by overnight
incubation at 4 °C. The next day the plates were blocked with 2% BSA-PBS-T for 1.5 h at 4 °C.
Single freeze-thaw CSF aliquots from both odd and even hours were thawed on ice. They were
diluted in a final buffer consisting of 2 mg/mL BSA-PBS-T, 3M Tris, 10% Azide, 1X protease
inhibitor cocktail. Samples were randomly assigned a well on the plate. Diluted CSF samples
and standards were pipetted at a volume of 50 µL per well onto freshly washed plates. The
samples were loaded in triplicate and incubated overnight at 4 °C. After incubation and washing,
the plates were incubated with HJ5.1-Biotin (Aβ13-28) 0.2 µg/mL in 1% BSA-PBS-TG for 1.5 h
at 25 °C. Plates were then washed three times with 190 µL PBS-T, followed by incubation in
Strep-poly-HRP40 (RDI) 1:12,000 in 1% BSA-PBS-TG for 1.5 h at 25 °C. Plates were
subsequently washed three times with 190 µL PBS-T. They were then incubated with 50
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µL/well of Slow ELISA TMB (pre-warmed to 25 °C) for 5-30 min. Optical density (OD) was
read at 650 nm by using a Biotek Synergy 2 plate reader.
Quantification of Metabolites’ Concentrations.
Soluble APPα, sAPPβ, Aβ40, and Aβ42 concentration levels were quantified by using the Biotek
Gen5 software (version #1.08.4) based on the non-linear five parametric standard curves
generated from the recombinant sAPPα, sAPPβ, Aβ40, and Aβ42 standards. The OD values of
the CSF samples fell within the linear range of the standard curve and were converted to
concentration levels. The product of the concentration and the dilution factor was calculated to
determine the final CSF concentration of each protein.
Quantification of Total Protein Concentrations.
Total protein levels of each sample were measured by using a micro BCA protein assay kit
(Thermo Fisher Scientific, Inc.; Rockford, IL), as previously reported (Huang et al., 2012a). The
intra-sample coefficient of variation was 2% for duplicates.
Grouped Cosinor Analysis.
Serial sAPPα and sAPPβ concentrations were binned in 2 h increments as measures were made
from every other hour. Serial Aβ40 and Aβ42 concentrations were left unbinned because hourly
concentrations were measured. For each APP metabolite, each participant’s hourly metabolite’s
concentration was normalized to that metabolite’s mean concentration over 36 h. The
normalized value was calculated as a percentage of the participant’s mean (100*value/mean).
Hourly (Aβ40, and Aβ42) and bi-hourly (sAPPα and sAPPβ) concentrations of each metabolite
were averaged among all participants in each participant group to produce normalized mean 36 h
concentrations. Next, the linear rise over time that was observed for all metabolites was
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subtracted from the mean concentrations, as previously described (Huang et al, 2012a). A single
cosinor analysis was performed for each metabolite, as described previously (Huang et al.,
2012a). Briefly, a cosine transformation was applied to the time variable by using 24 h as the
default circadian cycle, and Graphpad Prism version 5.01 for Windows (GraphPad Software; San
Diego, CA) was used to estimate the parameters of the circadian patterns for each metabolite’s
fluctuations. Mesor (midline of the metabolite oscillation), amplitude (distance between the peak
and mesor), and amplitude-to-mesor ratio were calculated for each participant group. Student ttests and ANOVAs were used to determine whether there were differences in these parameters
between groups. Analyses were performed in GraphPad Prism v. 5.01.
Individual Cosinor Analysis.
For each participant, sAPPα, sAPPβ, Aβ40, and Aβ42 levels over 36 h were analyzed by using a
single cosinor analysis as described in the Grouped Cosinor Analysis section of Experimental
Methods and Study Design. Mesor, amplitude, and amplitude-to-mesor ratio were calculated for
each metabolite and each participant. Participant group averages of each parameter were taken.
Student t-tests and ANOVAs were used to determine whether there was a significant difference
in parameters between groups. Analyses were done in GraphPad Prism v. 5.01.
Statistical Analyses.
Analyses were performed using Microsoft Office Excel 2007 and GraphPad Prism v. 5.01.
Correlations of APP metabolites were measured by calculating the correlation coefficient
(Pearson r values are reported). Soluble APPα, sAPPβ, and sAPPβ/α ratio were compared
among groups by using a student’s t-test. 95% confidence intervals were reported.
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Results
Development of a Specific and Sensitive sAPPβ ELISA.
Although commercial sAPPβ ELISA kits were available (from Covance and Meso Scale
Discovery), we developed our own sAPPβ sandwich ELISA that was selective for sAPPβ and
sufficiently sensitive to detect this protein in human CSF (final protocol may be found in this
chapter’s Experimental Methods and Study Design section). We tested the specificity of this
assay by running a titration curve of the sAPPβ and sAPPα protein standards on the same
ELISA. The results demonstrated that this assay was specific for sAPPβ and that cross-reactivity
with sAPPα was negligible (Figure 2.2.). The optical density (OD) for the sAPPβ standard of
8.5 ng/mL was approximately the same as that for the sAPPα standard of 300 ng/mL. This
indicated that this ELISA was approximately 35-fold more selective for sAPPβ than for sAPPα.
The CSF OD values fell within a linear range of the sAPPβ standard curve and well above the
sAPPα (300 ng/mL) value. Given that in biological samples sAPPα and sAPPβ were nearly
equal in molar concentrations, this minimal cross-reactivity of sAPPα in the sAPPβ ELISA was
negligible. Thus, we concluded that any fluctuations we observed in sAPPβ levels using this
ELISA were attributed solely to sAPPβ and not to sAPPα. Diluted CSF samples fell within the
linear range of the assay.
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Figure 2.2. Specificity and selectivity of the sAPPβ ELISA.

Optimization of a Specific and Sensitive sAPPα ELISA.
The developed sAPPα ELISA was adapted from (Olsson et al., 2005). The capture antibody was
8E5 (the same as used for the sAPPβ ELISA). The detection antibody was biotinylated
monoclonal 6E10, reactive to APP672-687, also known as Aβ1-16 (Signet Covance; Dedham, MA).
The standards used for this assay were the same as described in this chapter’s Experimental
Methods and Study Design section. The sAPPα ELISA showed no cross-reactivity with the
sAPPβ synthetic standard (Figure 2.3.).
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Figure 2.3. Specificity and selectivity of the sAPPα ELISA.
The protocol on which we based our assay directed to incubate the samples concurrently with the
2° antibody (6E10) overnight at 4 °C. To determine whether this was the optimal procedure, we
ran two ELISAs (using aliquots of the same samples) under the same conditions, barring the 2°
antibody incubation step. For one plate, the samples and 6E10 were concurrently incubated; for
the other plate, the samples were incubated separately overnight at 4 °C, and the following day,
the wells were incubated with 6E10 for 1.5 h at 37 °C. As demonstrated (Figure 2.4.),
incubation of sample concurrently with 6E10 was slightly better than the separate incubation.
OD values of all the points of the standard curve were slightly higher in the ELISA with
concurrent incubation; therefore, all values were further away from the “noise.” Also, the
ELISA with concurrent incubation was slightly more sensitive as it only had the three lowest
standards at baseline versus the four lowest standards in the other ELISA. Therefore, we decided
to follow the protocol with concurrent sample and 6E10 incubation.
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Figure 2.4. Optimization of sAPPα ELISA. Concurrent incubation of secondary antibody
with sample for sAPPα ELISA provided better separation at the lower end of the standard
curve than separate incubations. Concurrent incubation only showed three lowest points
of standard curve at baseline, whereas separate incubation showed four points. All points
during concurrent incubation had higher OD values than separate incubation, thus in the
latter case all points were closer to “noise.”

At the beginning of the optimization process, we had trouble fitting the CSF OD values into the
range of the standard curve. These values verged on the lower end of the standard curve and
indicated that the CSF sAPPα values were significantly lower than reported in the literature
(Zetterberg et al., 2008; Sennvik et al., 2000; Vuletic et al., 2008; Lannfelt et al., 1995). We
hypothesized that this may have been due to a mistake in making the original dilutions of the
standards when they were first received. If the samples were actually more concentrated than we
had noted, then the CSF concentrations would be lower than expected. Purchasing new
standards and taking out the highest standard points, while adding standards at lower
concentrations allowed us to better place CSF OD values in the linear, middle part of the broad
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dynamic range of the standard curve (Figure 2.5.). With four dilutions of a CSF sample, we
were able to establish dilution-dependent concentrations. Based on the results, we chose 25-fold
as the working dilution for CSF. All the values of the CSF’s original concentration in four
humans were in a range of approximately 850-1600 ng/mL which was similar to reported values
(Zetterberg et al., 2008; Sennvik et al., 2000; Vuletic et al., 2008; Lannfelt et al., 1995).

Figure 2.5. Determination of dilution factor for CSF.

Circadian Patterns of APP Metabolites.
To determine APP processing over time within the same participant, temporal CSF samples from
a particular participant were randomly assigned a well position on four sandwich ELISAs:
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specific for sAPPα, sAPPβ, Aβ40, or Aβ42. This allowed for analysis of APP metabolite
concentrations in the CSF over time. To compare age and amyloid deposition effects on hourly
dynamics of APP metabolites, the Young Normal Control (YNC) group was compared to the
Amyloid- and Amyloid+ groups.
sAPPα and sAPPβ exhibit circadian patterns.
Cerebrospinal fluid sAPPα and sAPPβ hourly concentrations had significant fits to a 24 h cosinor
pattern in the YNC group. The average amplitude of the diurnal pattern for sAPPα was 3.1% ±
1.3% (SEM) (Figure 2.6.A). For sAPPβ, the average amplitude was 4.4% ± 1.6% (SEM)
(Figure 2.6.D).
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Figure 2.6. Diurnal patterns in APP metabolites. Cosinor fits applied to mean 36 h APP
metabolite concentrations in each group after adjusting the baseline for each participant
and subtracting out the group’s linear increase over time. Results from all three
participant groups are reported for sAPPα (A-C), sAPPβ (D-F), Aβ40 (G-I), and Aβ42(J-L).

sAPPα and sAPPβ Circadian Amplitudes Lower with Older Age.
When a 24 h cosine curve was fit to the three group-averaged sAPPα hourly concentrations, the
YNC group exhibited an amplitude significantly deviated from zero (3.1%) and significantly
greater than the Amyloid- (0.9%) and Amyloid+ (2%) groups (Figure 2.6.A-C). Similar
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findings were observed when a cosine curve was fit to the three group-averaged sAPPβ hourly
concentrations (Figure 2.6.D-F). Amplitude of sAPPβ for the YNC group was 4.4%, Amyloidwas 1.2%, and Amyloid+ was 2%. Amplitude of Aβ40 for the YNC group was 0.9%, Amyloidwas 3.2% and Amyloid+ was 2.6% (Figure 2.6.G-I). Amplitude of Aβ42 for the YNC group
was 2.9%, Amyloid- was 3.7%, and Amyloid+ was 2.6% (Figure 2.6.J-L).
Individual sAPPα and sAPPβ Amplitude-to-Mesor Values Decrease with Age.
To control for differences in average values of amplitude and mesor among participants, the
amplitude-to-mesor ratios were calculated for each group. In the YNC group, sAPPα amplitudeto-mesor ratio was, on average, 10.9% (min.: 2.3%, max.: 18.2%). Both the Amyloid- (6.7%;
Min: 1.2%, max.: 14.0%; *p = 0.01) and Amyloid+ (6.0%; min.: 1.5%, max.: 20.1%; *p = 0.01)
groups had significantly lower sAPPα amplitude-to-mesor ratios than YNC. There was no
significant difference between the Amyloid- and Amyloid+ groups (p = 0.6) (Table 2.1., Figure
2.7.B).
Similar trends were observed among groups for the sAPPβ amplitude-to-mesor ratio. In YNC,
the mean sAPPβ amplitude-to-mesor ratio was 14.4% (min.: 3.8%, max.: 21.2%). The Amyloid(8.2%; min.: 1.7%, max.: 19.9%; **p < 0.005) and Amyloid+ (9.2%; min.: 1.9%, max.: 23.3%;
*p = 0.02) groups had significantly lower sAPPβ amplitude-to-mesor ratios than YNC.
However, Amyloid- and Amyloid+ groups did not significantly differ from one another (p = 0.6)
(Table 2.2., Figure 2.7.D).
On the contrary, the Aβ40 amplitude-to-mesor ratio was not statistically different among all three
groups. In YNC, the mean Aβ40 amplitude-to-mesor ratio was 8.5% (min.: 2.2%, max.: 18.5%).
The Amyloid- group had a mean Aβ40 amplitude-to-mesor ratio of 9.1% (min.: 2.7%, max.:
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16%) and the Amyloid+ group had a mean Aβ40 amplitude-to-mesor ratio of 9.1% (min.: 2.8%,
max.: 24.4%). None of these groups’ Aβ40 amplitude-to-mesor ratios were significantly different
from one another (YNC vs. Amyloid-: p =0.7; YNC vs. Amyloid+: p =0.8; Amyloid- vs.
Amyloid+: p =1.0) (Table 2.3., Figure 2.7.F).
When Aβ42 amplitude-to-mesor ratio was measured, similar trends to the Aβ40 amplitude-tomesor ratios were observed. In YNC, the mean Aβ42 amplitude-to-mesor ratio was 9.4% (min.:
1.9%, max.: 18.5%). The Amyloid- group had a mean Aβ42 amplitude-to-mesor ratio of 8.04%
(min.: 3.6%, max.: 23.5%) and the Amyloid+ group had a mean Aβ42 amplitude-to-mesor ratio
of 8.0% (min.: 2.2%, max.: 22%). None of these groups’ Aβ42 amplitude-to-mesor ratios were
significantly different from one another (YNC vs. Amyloid-: p = 0.5; YNC vs. Amyloid+: p =
0.5; Amyloid- vs. Amyloid+: p = 1.0) (Table 2.4., Figure 2.7.H).
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Figure 2.7. Circadian rhythm parameters of four APP metabolites in YNC, Amyloid-, and
Amyloid+ groups. A) Group-averaged sAPPα amplitudes were not significantly different
between groups. B) The sAPPα amplitude-to-mesor ratio was highest in YNC and
significantly lower in Amyloid- (*p = 0.01) and Amyloid+ (*p = 0.01). There was no
significant difference between the Amyloid- and Amyloid+ groups (p = 0.6). C) Groupaveraged sAPPβ amplitudes were significantly higher in YNC than in Amyloid- (*p = 0.05)
and Amyloid+ (*p = 0.02). D) The sAPPβ amplitude-to-mesor ratio was highest in YNC
and significantly lower in Amyloid- (**p = 0.003) and Amyloid+ (*p = 0.02). There was no
significant difference between the Amyloid- and Amyloid+ groups (p = 0.6). E) Group30

averaged Aβ40 amplitude values were not significantly different between any of the
participant groups. F) Amplitude-to-Mesor ratios for Aβ40 amplitude were also not
significantly different among groups. G) Group-averaged Aβ42 amplitudes were
significantly highest in YNC when compared to Amyloid- (*p = 0.04) and Amyloid+ (***p <
0.0001). The Amyloid- group also had a significantly higher Aβ42 amplitude than the
Amyloid+ group (***p < 0.001). H) The Aβ42 amplitude-to-mesor ratios did not different
significantly among groups.

Table 2.1. Comparison of cosinor parameters for sAPPα among 3 participant groups
Participant Group
YNC (n=13)
Amyloid- (n=19)
Amyloid+ (n=17)

Amplitude, ng/mL

Mesor, ng/mL

Mean (SD)

Mean (SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

75.7 (40.2)
59.2 (36.3)
51.1 (40.1)

731.0 (312.4)
1100.0 (694.8)
898.1 (300.8)

10.9 (5.4)
6.7 (3.8)
6.0 (4.7)

Table 2.1. Comparison of Cosinor Parameters for sAPPα among 3 participant groups.
Abbreviations: YNC: participants classified as young (cognitively) normal healthy
controls; Amyloid-: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, had a mean CSF Aβ42 concentration
> 350 pg/mL; Amyloid+: participants with MCBP greater than 0.18, or, in the absence of
MCBP measurements, had a mean CSF Aβ42 concentration less than 350 pg/mL.
Table 2.2. Comparison of cosinor parameters for sAPPβ among 3 participant groups
Participant Group
YNC (n=13)
Amyloid- (n=19)
Amyloid+ (n=17)

Amplitude, ng/mL

Mesor, ng/mL

Mean (SD)

Mean (SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

54.6 (21.3)
32.8 (33.4)
31.6 (27.8)

416.5 (181.7)
383.2 (208.2)
344.3 (221.1)

14.4 (5.7)
8.2 (5.3)
9.2 (5.7)

Table 2.2. Comparison of Cosinor Parameters for sAPPβ among 3 participant groups.
Abbreviations: YNC: participants classified as young (cognitively) normal healthy
controls; Amyloid-: participants with a Mean Cortical Binding Potential (MCBP) less than
0.18, or, in the absence of MCBP measurements, had a mean CSF Aβ42 concentration > 350
pg/mL; Amyloid+: participants with MCBP greater than 0.18, or, in the absence of MCBP
measurements, had a mean CSF Aβ42 concentration less than 350 pg/mL.
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Table 2.3. Comparison of cosinor parameters for Aβ40 among 3 participant groups
Participant Group
YNC (n=13)
Amyloid- (n=15)
Amyloid+ (n=14)

Amplitude, pg/mL

Mesor, pg/mL

Amplitude-to-Mesor Ratio, %

Mean (SD)

Mean (SD)

Mean (SD)

698.8 (518.6)
526.3 (311.0)
505.5 (365.5)

8966.0 (3375.3)
6373.0 (2951.2)
5872.0 (2977.5)

8.5 (5.5)
9.1 (4.6)
9.1 (5.7)

Table 2.3. Comparison of Cosinor Parameters for Aβ40 among 3 participant groups.
Abbreviations: YNC: participants classified as young (cognitively) normal healthy
controls; Amyloid-: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, had a mean CSF Aβ42 concentration
> 350 pg/mL; Amyloid+: participants with MCBP greater than 0.18, or, in the absence of
MCBP measurements, had a mean CSF Aβ42 concentration less than 350 pg/mL.
Table 2.4. Comparison of cosinor parameters for Aβ42 among 3 participant groups
Participant Group
YNC (n=13)
Amyloid- (n=15)
Amyloid+ (n=14)

Amplitude, pg/mL

Mesor, pg/mL

Mean (SD)

Mean (SD)

Amplitude-to-Mesor Ratio, %
Mean (SD)

64.3 (36.3)
39.5 (22.9)
14.5 (10.2)

830.7 (423.9)
518.6 (209.5)
206.9 (100.0)

9.4 (5.7)
8.0 (4.7)
8.0 (6.2)

Table 2.4. Comparison of Cosinor Parameters for Aβ42 among 3 participant groups.
Abbreviations: YNC: participants classified as young (cognitively) normal healthy
controls; Amyloid-: participants with a Mean Cortical Binding Potential (MCBP) less
than 0.18, or, in the absence of MCBP measurements, had a mean CSF Aβ42 concentration
> 350 pg/mL; Amyloid+: participants with MCBP greater than 0.18, or, in the absence of
MCBP measurements, had a mean CSF Aβ42 concentration less than 350 pg/mL.

Individual Aβ42 Amplitude Values Decrease with Age and Amyloidosis. sAPPβ Amplitude
decreases with Age.
On average, for YNC the sAPPα amplitude was 75.7 ng/mL (min.: 7.7 ng/mL, max.: 139.1
ng/mL), in Amyloid- it was 59.2 ng/mL (min.: 15.1 ng/mL, max.: 149.7 ng/mL), and in
Amyloid+ it was 51.1 ng/mL (min.: 15.3 ng/mL, max.: 155.8 ng/mL). Although a trend toward a
decrease of sAPPα amplitude with increase in age was observed, the groups were not
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significantly different by their sAPPα mean amplitudes (YNC vs. Amyloid-: p = 0.2; YNC vs.
Amyloid+: p = 0.1; Amyloid- vs. Amyloid+: p = 0.5) (Table 2.1.; Figure 2.7.A.).
However, there was a significant difference in YNC from the Amyloid- and Amyloid+ groups
with respect to sAPPβ mean amplitudes. The sAPPβ mean amplitude in the YNC group was
54.6 ng/mL (min.: 21.8 ng/mL, max.: 92.2 ng/mL). The Amyloid- group had a mean sAPPβ
amplitude that was 40% lower (32.8 ng/mL; min.: 5.4 ng/mL, max.: 111.1 ng/mL) than YNC (p
= 0.05), whereas the Amyloid+ group had a mean sAPPβ amplitude that was 42% lower (31.57
ng/mL; min.: 2.4 ng/mL, max.: 93.7 ng/mL) than YNC (*p = 0.02). There was no significant
difference in sAPPβ amplitude between the Amyloid- and Amyloid+ groups (p = 0.9) (Table
2.2.; Figure 2.7.C).
For the YNC group, the mean Aβ40 amplitude was 699 pg/mL (min.: 287 pg/mL, max.: 1834
pg/mL). There was a trend for decreased mean Aβ40 amplitude with age: the Amyloid- group
had a mean Aβ40 amplitude of 526 pg/mL (min.: 148 pg/mL, max.: 1138 pg/mL) and the
Amyloid+ group had a mean Aβ40 amplitude of 506 pg/mL (min.: 91 pg/mL, max.: 1381
pg/mL). This trend did not reach statistical significance (YNC vs. Amyloid-: p = 0.3; YNC vs.
Amyloid+: p = 0.3; Amyloid- vs. Amyloid+: p = 0.9) (Table 2.3.; Figure 2.7.E).
In contrast, the mean Aβ42 amplitudes were significantly different among each group. For the
YNC, the mean Aβ42 amplitude was 64.3 pg/mL (min.: 10.6 pg/mL, max.: 130.1 pg/mL). The
Amyloid- group had a mean Aβ42 amplitude that was 39% lower (39.5 pg/mL; min.: 14.4 pg/mL,
max.: 99 pg/mL) than the YNC group (*p < 0.05). The Amyloid+ group had a mean Aβ42
amplitude that was 77% lower (14.5 pg/mL; min.: 3.7 pg/mL, max.: 41 pg/mL) than the YNC
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group (***p <0.0001) and 63% lower than the Amyloid- group (**p < 0.001) (Table 2.4; Figure
2.7.G).
Individual Aβ42 Mesor Values Decrease with Age and Amyloidosis. Aβ40 Amplitude
Decreases with Age.
In YNC, sAPPα levels had a mean mesor over 36 h of 731 ng/mL (min.: 250 ng/mL, max.: 1254
ng/mL) (Table 2.1.). In Amyloid-, sAPPα levels displayed a mean mesor of 1100 ng/mL (min.:
192 ng/mL, max.: 2805 ng/mL). The Amyloid+ group had a sAPPα mesor level of 898ng/mL
(min.: 386 ng/mL, max.: 1353 ng/mL). None of these groups’ mesors were significantly
different from one another (YNC vs. Amyloid-: p = 0.2; YNC vs. Amyloid+: p = 0.08; Amyloidvs. Amyloid+: p = 0.3) (Table 2.1.).
The mean sAPPβ mesor in the YNC group was 417 ng/mL (min.: 229 ng/mL, max.: 928 ng/mL).
This was not significantly different (p = 0.6) from the mean sAPPβ mesor in Amyloid- (383
ng/mL; min.: 101 ng/mL, max.: 832 ng/mL), nor from the mean sAPPβ mesor level in Amyloid+
(344 ng/mL; min.: 118 ng/mL, max.: 900 ng/mL; p = 0.4). The mean sAPPβ mesors in the
Amyloid- and Amyloid+ groups were also not significantly different from one another (p = 0.6)
(Table 2.2.).
The YNC group had a mean Aβ40 mesor of 8966 pg/mL (min.: 2430 pg/mL, max.: 13433
pg/mL). The Amyloid- group had a 29% lower mean Aβ40 mesor (6373 pg/mL; min.: 1332
pg/mL, max.: 11089 pg/mL; *p < 0.05) than the YNC group. The Amyloid+ group exhibited a
35% lower Aβ40 mesor (5872 pg/mL; min.: 1505 pg/mL, max.: 10768 pg/mL; *p = 0.02) than
the YNC group. There was no statistically significant difference in mean Aβ40 mesor values
between the Amyloid- and Amyloid+ groups (p = 0.7) (Table 2.3.).
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The mean Aβ42 mesors were significantly different among each group. On average, the YNC
group’s Aβ42 mesor was 831 pg/mL (min.: 256 pg/mL, max.: 1683 pg/mL). The Amyloidgroup had a 38% lower mean Aβ42 mesor (519 pg/mL; min.: 195 pg/mL, max.: 885 pg/mL; p =
0.02) than the YNC group. The Amyloid+ group had a 75% lower mean Aβ42 mesor (207
pg/mL; min.: 48.9 pg/mL, max.: 471 pg/mL; p <0.0001) than the YNC group and a 60% lower
mean Aβ42 mesor than the Amyloid- group (p <0.0001) (Table 2.4.).
No Diurnal Pattern Exhibited in Total Protein Levels.
As a negative control for diurnal rhythms, we assayed total CSF protein over 36 h using a micro
BCA assay. We measured that, on average, total protein concentrations were significantly lower
in YNC as compared with the older participants (YNC = 792.8 μg/mL, Amyloid- = 895.1 μg/mL,
and Amyloid+ = 871.4 μg/mL, ***p < 0.0001). A cosinor fit was applied to the mean of each
group’s total protein level, and showed no significant circadian pattern in any of the groups (p >
0.05) (Figure 2.8.). Therefore, the observed CSF sAPPα, sAPPβ, Aβ40 and Aβ42 diurnal
patterns presented here appear to be independent of potential systemic diurnal changes in CSF
total protein.
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Figure 2.8. Cosinor-fitted group-averaged total protein concentrations determined using a
micro BCA assay. No significant diurnal patterns were apparent (p > 0.05 for each group).

Soluble APP and Aβ Positively Correlated, except in Amyloidosis.
To determine the relationship of α- and β-secretases on APP processing, correlations were
calculated for the average values of sAPPα, sAPPβ, Aβ40, and Aβ42 in three groups of
individuals: YNC, Amyloid-, and Amyloid+. Soluble APPα and sAPPβ were positively
correlated in all groups (YNC: r = 0.95, ***p <0.0001; Amyloid-: r = 0.93, ***p <0.0001;
Amyloid+: r = 0.86, **p < 0.002) (Figure 2.9.A). Soluble APPβ was positively correlated to
Aβ40 in YNC (r = 0.84, *p < 0.02), and Amyloid- groups (r = 0.68, **p < 0.005), but not in the
Amyloid+ group (r = 0.25, p = 0.5) (Figure 2.9.B). Soluble APPα trended towards a positive
correlation with Aβ40 in YNC (r = 0.69, p = 0.09) and was positively correlated in the Amyloidgroup (r = 0.84, **p < 0.003), but not in the Amyloid+ group (r = 0.2, p =0.6) (Figure 2.9.D).
There was a trend for sAPPβ to be positively correlated to Aβ42 in YNC (r = 0.57, p =0.2), and
Amyloid- groups (r = 0.5, p = 0.1); but not in the Amyloid+ group (r = -0.08, p =0.8) (Figure
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2.9.C). Similarly, sAPPα also trended to positive correlation with Aβ42 in YNC (r = 0.39, p
=0.4) and Amyloid- groups (r = 0.64, p < 0.05); but not in the Amyloid+ group (r =-0.01, p =
0.97) (Figure 2.9.E).

Figure 2.9. Correlations between APP metabolites. Amyloid Precursor Protein
metabolites in the first CSF collection for each participant were correlated to determine
relationships between the APP processing pathways. Each participant’s cerebrospinal
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fluid sample was drawn between 7:30AM-9:00AM. The four APP metabolites’
concentrations were measured using four separate metabolite-specific ELISAs, and, for
each participant, plotted against one another. The correlation coefficient was then
calculated for each group. A) sAPPα and sAPPβ concentrations for each participant were
plotted against one another and showed a positive correlation in all groups (YNC: r = 0.95,
***p <0.0001; Amyloid-: r = 0.93, ***p < 0.0001; Amyloid+: r = 0.86, **p < 0.002). B)
sAPPβ and Aβ40 concentrations for each participant were plotted against one another :
YNC: r = 0.84, *p < 0.05; Amyloid-: r = 0.68, **p < 0.005; Amyloid+: r = 0.25, p = 0.5). C)
sAPPβ and Aβ42 concentrations for each participant were plotted against one another and
a positive correlation was detected in YNC (r = 0.57, p = 0.2) and Amyloid- groups (r = 0.5,
p = 0.14), but no correlation was detected in the Amyloid+ group (r = -0.08, p = 0.8). D)
sAPPα and Aβ40 concentrations for each participant were plotted against one another and
compared among the groups: YNC: r = 0.69, p = 0.09; Amyloid-: r = 0.84, **p < 0.003;
Amyloid+: r = 0.2, p = 0.6). E) sAPPα and Aβ42 concentrations for each participant were
plotted against one another. The correlation results are as follows: YNC (r = 0.39, p = 0.4);
Amyloid- (r = 0.64, p < 0.05); and Amyloid+ (r = -0.01, p = 1.0).

sAPPβ/sAPPα Ratio is Elevated in Amyloidosis.
In order to determine the effects of age and amyloidosis on the APP processing pathways, APP
metabolites were compared among 3 groups: YNC, Amyloid-, and Amyloid+. The sAPPβ to
sAPPα ratio was 0.26 (≈1:3 ratio,  0.01, n = 15) in YNC, and 0.26 (≈1:3 ratio,  0.02, n = 16) in
Amyloid-. However, it increased to 0.32 (≈1:2 ratio,  0.05, n = 10) for Amyloid+. The
sAPPβ/sAPPα ratio was significantly higher in Amyloid+ participants than in Amyloid- (*p
=0.02) and YNC (**p =0.002) (Figure 2.10.A). However, independent sAPPα and sAPPβ
values were not significantly different between groups, suggesting that the sAPPβ/sAPPα ratio
corrected for other variances which were not associated with amyloidosis (Figure 2.10.B-C).
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Figure 2.10. Separating participant groups by the sAPPβ/sAPPα ratio. We compared
sAPPβ and sAPPα concentrations, as well as the sAPPβ/sAPPα ratio, among groups using
in the first CSF collection. Each participant’s first CSF sample was drawn between
7:30AM-9:00AM. sAPPβ and sAPPα concentrations were measured using two separate
metabolite-specific ELISAs. Student’s t-test was used and graphs show 95% Confidence
Interval error bars. A) sAPPβ/sAPPα ratio was higher with amyloid deposition
(Amyloid+) as compared to healthy, older controls (Amyloid-) (*p = 0.02) or young healthy
controls (YNC) (**p = 0.002). No significant difference was detected between the ratio of
the YNC and Amyloid- groups (p = 0.64). B) sAPPα concentrations were not significantly
higher in Amyloid+ than in YNC (p = 1.0) or Amyloid- (p = 0.5). No significant difference
was detected between the sAPPα concentration of the YNC and Amyloid- groups (p = 0.4).
C) sAPPβ concentrations were not significantly higher in Amyloid+ than in YNC (p = 0.09)
nor Amyloid- (p = 0.6). No significant difference was detected between sAPPβ
concentrations from the YNC and Amyloid- groups (p = 0.3).

Discussion
We evaluated whether APP exhibited diurnal fluctuations similar to that of Aβ, which would
help inform why Aβ demonstrated a diurnal pattern. We also determined normal α- and βprocessing of APP in the human CNS, and assessed whether AD pathology is associated with
alterations in APP processing.
The regulation of α- and β-secretase over time, including potential dynamic changes of sAPPα
and sAPPβ within an individual, were not previously evaluated, although Aβ diurnal activity was
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described in healthy, young human participants (Bateman et al., 2007). We recently
demonstrated that both in CSF (Huang et al., 2012a), and in plasma (Huang et al., 2012b), the
physiological Aβ diurnal fluctuation described in young participants diminishes significantly
with increasing age, but is not further decreased in amyloidosis. Further, previous studies in
mice indicated that sleep regulation may play a critical role in the risk and development of AD
(Kang et al., 2009), but more recent findings indicated that it may be Aβ aggregation that
disrupted both the sleep-wake cycle and Aβ diurnal fluctuation (Roh et al., 2012). For example,
longitudinal studies found a strong relationship between sleep circadian patterns as well as sleep
disordered breathing and risk of MCI and AD (Yaffe et al., 2011; Tranah et al., 2011).
Therefore, we sought to determine the relationship between α- and β- processing pathways in
individuals over time, and also determine if APP regulation contributes to Aβ circadian patterns.
In the YNC group, we found that sAPPα, sAPPβ, Aβ40, and Aβ42 concentrations were dynamic
over 36 h, with diurnal patterns. The lowest concentrations were in the morning (approximately
9AM), and the concentrations peaked in the evening, 12 h later. This suggests that in YNC
dynamic changes in these protein levels were due to dynamic changes in APP availability,
whether by its production (transcription or translation) or transport to the site of processing (i.e.
axonal transport). Amyloid-β also demonstrated a diurnal pattern with a peak and trough
approximately 3 h after sAPPα and sAPPβ. This suggests that APP diurnal availability likely
plays a role in Aβ diurnal patterns.
Diurnal patterns of sAPPα and sAPPβ were diminished in the Amyloid- group. Aβ40, and Aβ42
did not show any significant diurnal pattern in the Amyloid- group similar to prior work from our
laboratory (Huang et al., 2012a). Taken together, these findings indicated that with age, there
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was a loss of APP dynamics or availability, which resulted in the noted loss of not only sAPP,
but also Aβ, diurnal patterns.
A diurnal pattern of sAPPα and sAPPβ was also not seen to a similar extent in the Amyloid+
group as in the Amyloid- group. However, the diurnal patterns in Aβ40 and Aβ42 were even
more significantly diminished in the Amyloid+ group than in the Amyloid- group. This further
marked decrease in Aβ40 and Aβ42 diurnal patterns in the presence of amyloidosis did not
correspond to any decrease in sAPP diurnal patterns. This disconnect may be an effect of
downstream APP cleavage events and not due to APP dynamics or availability, which seems to
be the case in general aging. Potentially the extent of γ-secretase cleavage, which is controlled
by availability of the γ-secretase components or the γ-secretase level of activity, may play a role
in diminishing the diurnal patterns of the two Aβ species we measured.
Further, sAPPα and sAPPβ were positively correlated in all groups. Positive correlation of the αand β-secretase products suggested that for the non-competitive model of APP pathways, the
total APP availability drove changes in sAPPα and sAPPβ. Soluble APPα and sAPPβ were
positively correlated with both Aβ species in YNC and elderly controls. However, the
correlation between the sAPP species and Aβ42 was lost with amyloidosis. Previously reported
results taken in the human CNS showed a positive sAPPα to sAPPβ correlation between
individuals also suggesting non-competitive α- and β-pathways (Lewczuk et al., 2010; Gabelle et
al., 2010; Alexopolous et al., 2011). However, in vitro studies of inhibitors or activators, or
genetically decreasing BACE1 (a β-secretase protein) or ADAM10 (an α-secretase protein)
(Caporaso et al., 1992; Buxbaum et al., 1993; Savage et al., 1998; Skovronsky et al., 2000; Kim
et al., 2009; May et al., 2011) supported the hypothesis that α- and β-secretase pathways compete
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for the same APP pool owing to inverse correlations during inhibition of secretases (i.e. when
processing through one pathway decreases, the processing of the alternative pathway increases).
These studies suggested that there may be an inverse relationship between the α- and βpathways in inhibitor studies, whereas our study showed that during physiologic APP processing
in the human CNS, α- and β- processing were positively correlated.
We found that the molar ratio of sAPPα to sAPPβ was approximately 3:1 with a shift from α- to
β-processing in the setting of amyloid deposition to 2:1. The ratio difference between these
groups was not age-related because there was no significant difference between YNC and
Amyloid- groups. Prior reports estimated α to β ratios of 10:1 (Buxbaum et al., 1993,
Skovronsky et al., 2000); however, these estimates, made for an in vitro situation, likely had
lower β-secretase activity than is truly present in the CNS, because β-secretase is mostly found in
the brain (Vassar et al., 1999, Yan et al., 1999; Lin et al., 2000). We further showed that on
average sAPPβ/sAPPα was significantly higher in Amyloid+ participants than in Amyloidparticipants and YNC; therefore the ratio may be a useful indicator of Aβ plaque deposition.
These results are consistent with recent findings of increased CSF sAPPβ in the presence of
decreased Aβ42 and increased tau (Gabelle et al., 2010, Lewczuk et al., 2010). However, some
reports indicate increased sAPPα (Alexopoulos et al., 2011) whereas others show no difference
(Gabelle et al., 2010, Lewczuk et al., 2010), similar to our findings. To summarize, amyloidosis,
not age, was associated with a constitutive change in the β- to α- APP processing between
individuals.
In conclusion, we show that diurnal dynamics of APP metabolites diminished with age, and, only
for Aβ, were further attenuated with amyloidosis. These results may confound other studies’ data
of sAPPα, sAPPβ, Aβ40, and Aβ42 levels in AD versus non-AD participants where CSF was
42

collected and metabolites were measured at a single time point. This may explain the wide range
of concentrations of metabolites presented from various groups. We also indicate that taking a
ratio of sAPPβ/sAPPα may correct for these inconsistencies. Further, we demonstrated that there
was a positive correlation among soluble APP metabolites, which diminished with amyloidosis.
This dissociation was probably due to CSF Aβ42 levels in AD no longer being representative of
APP processing owing to the sequestering of Aβ, particularly Aβ42, in plaques.
Attributes of this study included sampling from the human CNS in three different groups where
total protein showed stability over time. Therefore, CSF APP dynamics seem to be independent
of CSF total protein levels. However, we did not directly measure α- and β-secretase activities
or production rates of APP metabolites. Our study does not answer the question of what causes
APP to rise and fall in a diurnal pattern and does not allow us to distinguish among potential
reasons, such as transcription, translation, or transport. A potential caveat to the study is that
about 30% of our Amyloid- subject group had a CDR > 0, indicating that they may have
dementia other than Alzheimer’s disease. If a CDR+ subject has no significant amyloid plaque
deposition and/or the subject’s Aβ42 level below 350 pg/mL (is considered Amyloid-), we
presume that the potential non-AD dementia that they may have is not associated with APP
processing since free Aβ, as well as Aβ in plaques, isn’t affected. That being said, removing
Amyloid- subjects who were CDR+ from our analyses did not alter the significance of the
observed trends, or lack thereof. Future studies into APP processing pathways, including
production rates of APP and α- and β-secretases should be able to inform about causes of APP
dynamics.
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Chapter 3 Soluble Amyloid Precursor Protein
Turnover Rates in Healthy, Young Humans
Introduction
In 2006, our group reported the initial Aβ turnover rates in young, healthy humans. The
Fractional Synthesis Rate (FSR) and the Fractional Clearance Rate (FCR) were calculated in six
participants, and were determined to be 7.6%/h and 8.3%/h, respectively (Figure 3.1.) (Bateman
et al., 2006).

Figure 3.1. Metabolism of Aβ in healthy young humans (n=6) (Bateman et al., 2006).

As Aβ is a metabolite of the larger Amyloid Precursor Protein, we decided to investigate the
metabolism (production and clearance rates) of total soluble APP. Using 8E5 antibody bound to
CNBr-activated SepharoseTM 4B beads, we isolated total sAPP from CSF (collected over a 36 h
13

time course, at beginning of which the participant was infused with C6-leucine) and H4 media
that was labeled at 1.25%, 2.5%, 5%, 10%, 20%, or unlabeled (0%). This media contained
similar amounts of sAPP as found in human CSF and was, therefore, used as a standard to
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generate a standard curve. Soluble APP isolated from CSF/media was then proteolytically
cleaved with trypsin, and the digested sample was injected onto an HPLC column. We measured
the production and clearance rates based on the tryptic unlabeled and labeled peptides:
EQNYSDDVL(L*)ANMISEPR (the labeled peptide was 6 Da heavier because the label on the
13

leucine was C6). Both the labeled and unlabeled tryptic peptides eluted from the HPLC
column and were ionized at the same time. The precursor ions were separated based on mass-to2

charge ratio (m/z). The two ions of interest were further fragmented into MS (“product”) ions
that were also separated by m/z. The labeled product ions were either 3 or 6 Da heavier than the
unlabeled product ions depending on the charge of the ion. A computer program, SILTmass,
(written by V. Ovod and D. Elbert at Washington University in St. Louis) was used to determine
the ratio of the labeled to unlabeled product ions of interest. The fractional synthesis rate (FSR)
was calculated based on the slope to precursor ratio. The precursor ratio of 9.86% was
calculated based on the total available labeled and unlabeled leucine.

Experimental Methods and Study Design
Participants and Sample Collection.
Participants (Young Normal Controls) were recruited from the general public after approval by
the Washington University Human Studies Committee and the General Clinical Research Center
(GCRC) Advisory Committee. Three Caucasian male participants under the age of 60 years
were assessed in this study (age at time of study: 23.4 yrs., 25.5 yrs., and 58.9 yrs.). The ApoE
genotype was available only for the third participant; he had two copies of the ApoE-ε3 allele.
After informed consent was obtained, participants were screened to determine that they were in
good general health and without any neurologic diseases. Participants fasted for 11 h prior to
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admittance into the study, at 7:00 A.M. During the course of the study, the GCRC kitchen
provided participants with free access to water and three daily meals at set times: 9:00 A.M.,
1:00 P.M., and 6:00 P.M. To avoid potential confounding effects on the labeled leucine infusion
study, the meals provided to participants were low in leucine. Meals consisted of approximately
60% carbohydrates, 20% fat, and 20% protein. Participants had an intravenous (IV) catheter
placed in one of their contra-lateral antecubital veins to collect 12 mL of blood hourly for 36 h,
except between 11:00 P.M. and 7:00 A.M. when collection occurred bihourly. A subarachnoid
catheter was inserted into the lumbar region, L3-L4 interspace, using a Touhy needle, so as to
allow for serial CSF sampling without the need for multiple lumbar punctures. During the
course of the 36 h study, 6 mL CSF was sampled hourly. Both blood and CSF samples were
apportioned into 1 mL aliquots in Axygen maximum-recovery polypropylene tubes. The
samples were immediately frozen and stored at -80 °C. Once the participants were catheterized,
they were discouraged from leaving their bed, except for restroom use.
13

C6-Leucine infusion protocol.

Prior to study onset, an intravenous catheter, through which stable isotope labeled leucine
solution would be administered, was placed in each participant’s antecubital vein. One day prior
13

to the study, the C6-labeled leucine (Cambridge Isotope Laboratories, Inc.; Andover, MA) was
prepared by dissolution in medical grade normal saline solution and filtration through a 0.22μm
13

filter. Administration of C6-labeled leucine took place with an initial bolus of 2 mg/kg over 10
min to reach a steady state of labeled leucine. This was immediately followed by a continuous
intravenous infusion with a medical IV pump at a rate of 1.8, 2.0, or 2.5 mg/kg/h for 9 h.
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Cell Culture and Media Standards.
Immortalized human H4 neuroglioma cells stably transfected with human APP751 (H4-APPwt)
(courtesy of T. E. Golde Laboratory, UF-Gainesville) were grown in Dulbecco's Modified Eagle
Medium (DMEM) with 10% Fetal Bovine Serum (FBS) and passaged twice. Leucine-free
DMEM, containing no serum, was obtained from the Washington University Tissue Culture
13

Support Center and supplemented with a mixture of C6-labeled leucine solution such that the
total final leucine concentration was the same as in standard DMEM (105 mg/L). The final
media solutions had: 0%, 1.25%, 2.5%, 5%, 10%, or 20%

13

C6-leucine. Labeled DMEM was

supplemented with 1:50 B-27 (a serum-free supplement) and 1% each of Penicillin-Streptomycin
and Zeocin (antibiotics). During the third passage, cells were pooled and split evenly. The H4APPwt cells were reconstituted in one of the six prepared media solutions and cultured for 24 h to
13

allow for sufficient incorporation of C6-leucine into proteins, such as APP. Following the
incubation with labeled DMEM, the media solutions were collected and analyzed by ELISA to
determine that they contained similar concentrations of sAPP as the human CSF samples. The
labeled media was then apportioned into Axygen tubes in 1 mL aliquots and immediately frozen
and stored at -80 °C.
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Figure 3.2. Human labeled leucine infusion protocol and sample collection. A human
participant enrolled in the study was catheterized prior to the study onset. Continuous
13
intravenous C6-labeled leucine infusion occured at a rate of 2mg/kg/h for 9 h, following
an initial bolus infusion of 2 mg/kg over 10 min. Through the lumbar catheter, CSF (6
mL) was collected hourly. Simultaneously, blood (12 mL) was collected hourly or bihourly.
Cerebrospinal fluid and blood sampling occured over the course of 36 h (Bateman et al.,
2006).

Immunoprecipitation and digestion of total sAPP.
We sought to determine total sAPP production and clearance rates in human CSF. To this end,
we first isolated total sAPP from the CSF and media standard samples by immunoprecipitation
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of the samples with beads bound to 8E5, a mid-domain APP monoclonal antibody (directed
against APP444-592, courtesy of Eli Lilly). To prepare the samples for IP we thawed them on ice:
13

1 mL of CSF per each time-point (for a total of 37 CSF samples) and a H4-APPwt C6-leucine
labeled media standard curve (1 mL media for each of the six points on the standard curve). We
added 100 μL of 5M Guanidine Tris (pH 8.0) and 12.5 μL protease inhibitor cocktail (40 μg/mL
aprotinin and 20 μg/mL leupeptin), and 30 μL of a 50% 8E5-bead slurry (prior to study onset,
CNBr-activated SepharoseTM 4B beads (GE Healthcare) were covalently bound to 8E5 antibody
(1mg/mL) in 0.02% Sodium Azide in PBS, and stored at 4 °C). We incubated the samples with
rotation overnight (approximately 18 h) at 4 °C. The next day the supernatant was removed and
the beads were rinsed three times with 25 mM ammonium bicarbonate (AmBic) and aspirated
until dry. The protein bound to the antibody-bead complex was then eluted with 50 µL formic
acid (FA) for two minutes. The eluant, containing the protein isolated from the sample, was
removed using a crimped gel loading tip, and placed into an Axygen maximum-recovery
polypropylene tube. Subsequently, the samples were evaporated in a rotary evaporator at 37 °C
until fully dry (approximately 30 min) and reconstituted in 25 µL of 10% acetonitrile (ACN) in
AmBiC. The isolated sAPP was proteolytically cleaved by 20 µL Sequencing Grade Modified
Trypsin (Promega; Madison, WI) during an overnight (approximately 18 h) incubation at 37 ºC.
Trypsin predominantly cleaves proteins at the carboxylic side of the amino acids Lysine (K) and
Arginine (R) except when either is bound to a C-terminal Proline (P). The doubly charged
([M+2H]+2) sAPP tryptic peptide used for quantitation in this study had the sequence:
EQNYSDDVL(L*)ANMISEPR (unlabeled: m/z = 990.95; labeled: m/z = 993.95).
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Figure 3.3. Isolation of Amyloid Precursor Protein from cerebrospinal fluid. Amyloid
Precursor Protein was immunoprecipitated from CSF or media standards overnight at 4
°C using 8E5 antibody-bound beads. After washing beads, trypsin was used to
proteolytically digest APP bound to the beads. Trypsin cleaves at the carboxylic side of
Lysine (K) and Arginine (R) residues, except when either is bound to a C-terminal Proline
(P).

Peptide quantitation by liquid chromatography-mass spectrometry (LC-MS).
The pre-determined tryptic peptides were quantified on a Thermo-Finnigan LTQ, a linear trap
quadrupole mass spectrometer, equipped with a New Objective nanoflow ESI source. The
peptides were separated by RP HPLC using an Eksigent 2D-LC nanoflow pump operating in 1D
mode at a flow rate of 200 nL/min. The digested sample (5 μL) of tryptic peptides was injected
onto a New Objective picofrit column packed to 12 cm with 5 μm Magic C18aq packing material
(Michrom). Mobile Phase A contained 0.1% formic acid (FA) in water and Mobile Phase B
contained 0.1% FA in acetonitrile (ACN). Both the labeled and unlabeled tryptic peptides eluted
from the HPLC column and were ionized simultaneously. The precursor ion was separated
based on mass-to-charge ratio (m/z). The doubly charged ([M+2H]+2) sAPP tryptic peptide used
for quantitation in this study had the sequence: EQNYSDDVL(L*)ANMISEPR (unlabeled: m/z
= 990.95; labeled: m/z = 993.95). These were further fragmented into b- and y- product ions that
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were also separated by m/z. The labeled product ions were 3 or 6 m/z heavier than the unlabeled
product ions depending on whether the ion was doubly or singly charged, respectively.

Figure 3.4. Liquid Chromatography-Mass Spectrometry analysis of sAPP peptides. The
labeled and unlabeled sAPP tryptic peptides (EQNYSDDVL(L*)ANMISEPR) that were
isolated from CSF/media standards were injected onto a nano-liquid chromatography
(nanoLC) column, from which they simultaneously eluted during the LC gradient. Eluted
peptides became charged in the electrospray and were then admitted to the LTQ mass
spectrometer. A pre-determined MS (“Precursor”) ion corresponding to that peptide was
then selected, based on the mass-to-charge ratio (m/z). The precursor ions were further
fragmented to produce “Product” ions that were also separated based on m/z.
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Figure 3.5. Precursor and product ion chromatograms and product ion mass spectra for
sAPP peptide. The upper panel shows representative chromatograms of the sAPP peptides
monitored (EQNYSDDVL(L*)ANMISEPR), which eluted at approximately 19.5 min into
the LC gradient. The lower panel presents the mass spectra of the unlabeled and labeled
product ions, with the observed, unique b- and y- product ion profile formed during
fragmentation.

Free Leucine Quantitation by gas-chromatography-mass spectrometry (GC-MS).
13

Cerebrospinal fluid C6-leucine enrichment was determined using gas capillary gas
chromatography mass spectrometry (GC-MS; Agilent 6890N gas chromatograph and Agilent
5973N mass selective detector) in negative chemical ionization mode as described previously
(Yarasheski et al., 1992, Bateman et al., 2007). As described in Wolfe et al. (2005),
enrichment was quantified as a tracer to tracee ratio (TTR).

52

13

C6-leucine

Quantitation of labeled ratio.
The percentage of labeled sAPP was determined by taking the ratio all of b- and y- product ion
intensities from the unlabeled and labeled peptide (EQNYSDDVL(L*)ANMISEPR) of APP444592.

The ratio was computed using a custom Microsoft Excel spreadsheet with macros. The

tandem MS quantification of labeled to unlabeled peptides that was used here is detailed in
Bateman et al. (2007a).
Quantitation of fractional synthesis rate and monoexponential slope fractional clearance
rate.
A fractional synthesis rate (FSR) and monoexponential slope fractional clearance rate (FCR) for
sAPP was quantified as previously reported (Wolfe et al., 2005). Briefly, FSR was calculated as
the slope of the labeled metabolite during the production phase (h: 5-14), divided by the CSF
13

C6-leucine enrichment which served as the precursor pool for APP synthesis. The standard

equation from Wolfe et al. (2005) was used:

2
(Et2 - Et1)sAPP

1

(t2 - t1) is defined as the slope of the line during the labeling period, and

Precursor E is the ratio of labeled free leucine to unlabeled free leucine. The slope of the linear
13

regression was calculated from 5 to 14 h and divided by the average of CSF C6-labeled leucine
level during the infusion period.
Monoexponential slope FCR was computed by fitting the slope of the natural logarithm of the
clearance phase of the sAPP labeling curve (h: 24 - 36). The standard equation monoexponential
FCR equation was used (Wolfe et al., 2005):
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Statistical Analyses.
Mean and standard deviation were calculated using Microsoft Office Excel 2007.

Results
Soluble APP Turnover Rate is Faster than Aβ Turnover Rate.
We calculated the sAPP FSR for three individuals and determined that the mean was 3.68%/h ±
0.19 (SD) (Figure 3.7). This compared to previous work done in our lab where Aβ FSR was
determined to be 7.6%/h in young healthy controls. Fractional clearance rate (FCR) of sAPP
was calculated and expressed as the natural log of labeled to unlabeled sAPP. The FCR was only
calculated in one participant because the two other participants’ labeled sAPP did not clear in the
36 h time course. The sAPP FCR for this individual was 4.74%/h (Figure 3.7). This compared
to the FCR of Aβ in young healthy controls which was 8.3%/h. A sample sAPP
labeled/unlabeled leucine curve (over 36 h) as measured in human CSF is provided (Figure 3.6),
as well as the FCR curve from the same participant.
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Figure 3.6. Total sAPP immunoprecipitated from human CSF was digested with trypsin,
13
and tryptic peptides containing C6-leucine were used to measure total sAPP kinetics. The
13
fractional synthesis rate (FSR) over 36 h was calculated from the C6-sAPP kinetic curve.
A) A representative metabolism curve of the sAPP peptide EQNYSDDVL(L*)ANMISEPR
from one participant used in quantitation of the kinetics of total sAPP after
immunoprecipitation with 8E5. Total sAPP FSR (production) in this participant was
3.9%/h. Total sAPP FCR for the same participant was 4.74%/h. B) H4 neuroglioma cells
13
were labeled with C6-leucine at 0%, 1.25%, 2.5%, 5%, 10%, and 20%. The cell media
was collected and a mid-domain APP antibody was used to immunoprecipitate total sAPP.
13
Isolated sAPP underwent proteolytic cleavage by trypsin. Quantitation of C6-leucine
labeled and unlabeled sAPP peptides for each media standard provided that media
standard’s observed percentage label of leucine. The observed value was plotted against
expected value for all 6 media standards, thus generating the standard curve which
demonstrates high accuracy and linearity (r2 = 0.998).
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Figure 3.7. Metabolism of total sAPP in healthy young humans (Dobrowolska et al., 2008).

Discussion
Although lacking a large sample size, in this experiment we were able to show some preliminary
data that indicated a faster turnover rate for Aβ as compared to total sAPP. Soluble APP FSR
was 3.68%/h whereas Aβ FSR had been previously determined to be 7.6%/h. The FCR for sAPP
was was 4.74%/h, whereas Aβ FCR had been previously determined to be 8.3%/h. We were
initially surprised that the turnover (both FSR and FCR) for sAPP was considerably slower than
Aβ. This was striking considering that Aβ is a later cleavage product of APP than either sAPPα
or sAPPβ, which were effectively both being measured in our sAPP calculations. We presumed
that the individual turnover rates of sAPPα and sAPPβ were markedly different, and perhaps our
slower turnover rate for sAPP was being driven by a slower turnover of APP processed through
the α-pathway, while the APP processing down the β-pathway was faster, and the turnover rate
of sAPPβ would be similar to the previously reported Aβ turnover rate. It is also possible that
our observations were solely an artifact of small sample size (n=3 for FSR and n=1 for FCR).
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There may be vast inter-subject variability for these FSRs and FCRs in humans, even in healthy
adults. Therefore, to test whether the phenomenon we observed (sAPP turnover was slower than
Aβ turnover) was not an artifact, we decided to develop a SILK method to measure sAPPα and
sAPPβ simultaneously from the same CSF sample and compare the turnover rates of the two
individual sAPPs to the turnover rate of Aβ. Such an analysis would encompass a large sample
size of YNC and AD human subjects. This method development is outlined in the following
chapter (4).
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Chapter 4 Method Development for sAPPα and sAPPβ
Kinetic Measurements in Healthy, Young Humans
Portions of this chapter appeared in Patent Pending Pub. No.: WO/2010/056815.

Introduction
As total sAPP production and clearance rates do not provide insight into the processing of sAPP
through the amyloidogenic versus the non-amyloidogenic pathway, we developed a novel LCMS assay that allowed us to quantitate sAPPα and sAPPβ kinetics in the same sample at the
same time. Samples were acquired and handled as described in Chapter 4 up until the proteolytic
digestion step. Instead of using the protease trypsin, we used Arginine-C (Arg-C)
(Worthington), which cleaves at the C-terminus of Arginine (R). Based on the positions of βsecretase, α-secretase, and Arg-C cleavage, two candidate peptides containing a leucine and
unique to either sAPPβ or sAPPα are produced (Figure 4.1.).

Figure 4.1. Amyloid Precursor Protein Sequence with positions of proteolytic cleavage,
antibody binding sites, and peptides chosen for quantitation.
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We monitored and calculated the ratio of labeled to unlabeled b- and y- product ions produced as
described in Chapter 3. However, this time the b- and y- product ions measured were derived
from different peptides. These peptides for sAPPβ are: 1) unlabeled:
PGSGLTNIKTEEISEVKM, [M+H]

+3

PGSGL*TNIKTEEISEVKM, [M+H]

of m/z = 645; and 2) labeled:

+3

of m/z = 647. The two peptides for sAPPα were almost

identical to those for sAPPβ, with the exception of having five additional amino acids at the C+4

terminal end of the peptide: 1) unlabeled: PGSGLTNIKTEEISEVKMDAEFR, [M+4H]
+4

= 638.98; 2) labeled: PGSGL*TNIKTEEISEVKMDAEFR, [M+4H]

of m/z

of m/z = 640.48. Elution

of the unlabeled and labeled sAPPβ peptides from the HPLC column occurred only 90 sec prior
to the elution of the unlabeled and labeled sAPPα peptides (Figure 4.6). This was a sufficient
2

separation in time to detect two separate quantifiable precursor ions and allow MS profiling of
distinct b- and y- ions for unlabeled versus labeled peptides (Figure 4.7).

Experimental Methods and Study Design
Participants and Sample Collection.
Participants (Young Normal Controls) were recruited from the general public after approval by
the Washington University Human Studies Committee and the General Clinical Research Center
(GCRC) Advisory Committee. A total of one participant was assessed in this study. After
informed consent was obtained, participants were screened to determine that they were in good
general health and without any neurologic diseases. Participants fasted for 11 h prior to
admittance into the study, at 7:00 A.M. During the course of the study, the GCRC kitchen
provided participants with free access to water and three daily meals at set times: 9:00 A.M.,
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1:00 P.M., and 6:00 P.M. To avoid potential confounding effects to the labeled leucine infusion
study, the meals provided to participants were low in leucine. Meals consisted of approximately
60% carbohydrates, 20% fat, and 20% protein. Participants had an intravenous (IV) catheter
placed in one of their contra-lateral antecubital veins to collect 12 mL of blood hourly for 36 h,
except between 11:00 P.M. and 7:00 A.M. when collection occurred bihourly. A subarachnoid
catheter was inserted into the lumbar region, L3-L4 interspace, using a Touhy needle, so as to
allow for serial CSF sampling without the need for multiple lumbar punctures. During the
course of the 48 h study, 6 mL CSF was sampled hourly. Both blood and CSF samples were
apportioned into 1 mL aliquots in Axygen maximum-recovery polypropylene tubes. The
samples were immediately frozen and stored at -80 °C. Once the participants were catheterized,
they were discouraged from leaving their bed, except for restroom use.
13

C6-Leucine infusion protocol.

Prior to study onset, an intravenous catheter, through which stable isotope labeled leucine
solution would be administered, was placed in each participant’s antecubital vein. One day prior
13

to the study, the C6-labeled leucine (Cambridge Isotope Laboratories, Inc. (Andover, MA))
was prepared by dissolution in medical grade normal saline solution and filtration through a 0.22
13

μm filter. Administration of C6-labeled leucine took place by an initial bolus of 2 mg/kg over
10 min to reach a steady state of labeled leucine. This was immediately followed by a
continuous intravenous infusion with a medical IV pump at a rate of 1.8, 2.0, or 2.5 mg/kg/h for
9 h.
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Cell Culture and Media Standards.
Chinese Hamster Ovary (CHO) cells were grown in Ham’s F12 media for two passages.
Leucine-free Ham’s F12 media was obtained and supplemented with a mixture of labeled leucine
solution in the concentration of leucine in regular Ham’s F12 media. Media solutions prepared
ahead of time: 0%, 1.25%, 2.5%, 5%, 10%, and 20% labeled. At the third passaging of the cells,
all the cells were pooled and split evenly. Cells were reconstituted in one of the six prepared
media solutions and grown for 22 h. Media was collected, aliquoted, and stored at -80 ºC.
Immunoprecipitation of total sAPP.
Cerebrospinal fluid, 1 mL every 2 h (total of 18 samples), and 1 mL of CHO media each for 0%,
13

1.25%, 2.5%, 5%, 10%, and 20% C6-leucine label were thawed on ice. To each of the samples
we added 100 μL 5M Guanidine Tris (pH 8.0) and 10μl of protease inhibitor cocktail (40 μg/mL
aprotinin and 20 μg/mL leupeptin). After rinsing steps, 60μl of 8E5-bound bead slurry
(Sepharose beads coupled to 8E5 antibody (1 mg/mL) in 0.02% sodium azide in Phosphate
Buffered) was added to each sample. To immunoprecipitate all species of sAPP, we rotated the
sample-antibody bead mixture overnight (18 h) at 4 °C. At the end of this period, the
supernatant was collected and the beads were rinsed three times with 25 mM ammonium
bicarbonate (AmBic).
Digestion of sAPP into sAPPα and sAPPβ specific peptides.
To digest the sAPP into peptides that will be specific for sAPPα or sAPPβ, we reconstituted the
beads with 25 μL 10% acetonitrile (ACN) in 25 mM AmBic. We added 160 ng of Arginine-C,
Calcium acetate (final molarity : 2 mM), and Dithiothreitol (DTT) (final molarity : 2.5 mM), to
this slurry. Digestion took place on a shaker for 18 h at 37 °C. When digestion concluded, we
added formic acid (FA) to the bead slurry in order to stop digestion (final: 5% FA). We
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incubated for another 30 min at 37 °C on a shaker. The supernatant from bead slurry was pulled
off with a crimped gel loading tip and transferred into new Eppendorf tube. The peptide mix was
desalted with 1% FA using NuTip Carbon Tips (Glygen Corp., Columbia, MD). Samples were
eluted in 80% ACN/1% FA and evaporated in a rotary evaporator until no solution was left.
Samples were reconstituted in 10% ACN in NH4HCO3.
Peptide quantitation by liquid chromatography-mass spectrometry (LC-MS).
Samples (5 μL) were injected onto a C18aq Aquasil Zorbax (3 μm) column. The two peptides we
monitored were: PGSGL(L*)TNIKTEEVMDAEFR (sAPPα) and PGSGL(L*)TNIKTEEVKM
(sAPPβ) and they eluted from the column approximately two minutes apart.
Free Leucine Quantitation by gas-chromatography-mass spectrometry (GC-MS).
13

Cerebrospinal fluid C6-leucine enrichment was determined using gas capillary gas
chromatography mass spectrometry (GC-MS; Agilent 6890N gas chromatograph and Agilent
5973N mass selective detector) in negative chemical ionization mode as described previously
(Yarasheski et al., 1992, Bateman et al., 2007). As described in Wolfe et al. (2005),

13

C6-leucine

enrichment was quantified as a tracer to tracee ratio (TTR).
Quantitation of labeled ratio.
The percentage of labeled sAPPα was determined by taking the ratio all of b- and y- product ion
intensities from the unlabeled and labeled peptide (PGSGL(L*)TNIKTEEVMDAEFR) of
APP444-592. The percentage of labeled sAPPβ was determined by taking the ratio all of b- and yproduct ion intensities from the unlabeled and labeled peptide (PGSGL(L*)TNIKTEEVKM) of
APP444-592. The ratio was computed using a custom Microsoft Excel spreadsheet with macros.
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The tandem MS quantification of labeled to unlabeled peptides that was used here is detailed in
Bateman et al. (2007a).
Quantitation of fractional synthesis rate and monoexponential slope fractional clearance
rate.
A fractional synthesis rate (FSR) and monoexponential slope fractional clearance rate (FCR) for
sAPP would have been quantified as previously reported (Wolfe et al., 2005) if the CSF labeling
curves were reliably quantifiable. Briefly, FSR would be calculated as the slope of the labeled
13

metabolite during the production phase (h: 5-14), divided by the CSF C6-leucine enrichment
which served as the precursor pool for APP synthesis. The standard equation from Wolfe et al.
(2005) was:
,

2

1

(Et2 - Et1)sAPPα,β ÷ (t2 - t1) is defined as the slope of the line during the labeling period, and
Precursor E is the ratio of labeled free leucine to unlabeled free leucine. The slope of the linear
13

regression would have been calculated from 5 to 14 h and divided by the average of CSF C6labeled leucine level during the infusion period.
Monoexponential slope FCR was computed by fitting the slope of the natural logarithm of the
clearance phase of the sAPP labeling curve (h: 24-36). The standard equation monoexponential
FCR equation was used (Wolfe et al., 2005):
,

ln

,
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Results
Representative chromatography elution profiles of labeled and unlabeled sAPPβ specific product
ions from a media standard sample are below (Figure 4.2.). Unlabeled and labeled peptides
elute from the HPLC column simultaneously, represented as a sharp, uncontaminated peaks that
are ideal for quantitation.

Figure 4.2. Chromatograms of labeled and unlabeled sAPPβ specific product ions from a
media standard sample. sAPPβ unlabeled and labeled peptides eluted from the HPLC
column simultaneously, and were ionized and fragmented in the mass spectrometer,
producing characteristic product ions.
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Representative mass spectra of labeled and unlabeled sAPPβ specific product ions from a CHO
media standard sample are below (Figure 4.3.). Unlabeled and labeled product ions are formed
from peptides that elute from the HPLC column simultaneously, as represented by sharp, single
peaks, which are ideal for quantitation.

Figure 4.3. Mass spectra of labeled and unlabeled sAPPβ-specific b- and y- product ions
from a CHO media standard sample. The retention time of the triply charged unlabeled
(PGSGLTNIKTEEVKM of m/z = 645.41) and labeled (PGSGL*TNIKTEEVKM of m/z =
647.41) sAPPβ peptide was approximately 23.3 min.

Representative chromatography elution profiles of labeled and unlabeled sAPPα peptides as
manifested by specific product-ion peaks from a media standard sample are below (Figure 4.4.).
Unlabeled and labeled peptides elute from the HPLC column simultaneously, and they are
fragmented in the mass spectrometer to produce characteristic product ions. The trailing peak
indicates some contamination. Signal-to-noise ratio strength would need to be higher for
quantitation.
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Figure 4.4. Chromatography elution profiles of labeled and unlabeled sAPPα tryptic
peptides as seen by peaks from a CHO media standard. sAPPα unlabeled and labeled
peptides eluted from the HPLC column simultaneously, and were ionized and fragmented
in the mass spectrometer to characteristic product ions.
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Representative mass spectra of labeled and unlabeled sAPPα specific product ions from a CHO
media standard sample are below (Figure 4.5.). Unlabeled and labeled product ions are formed
from peptides that elute from the HPLC column simultaneously, as represented by sharp, single
peaks, which are ideal for quantitation.

Figure 4.5. Mass spectra of labeled and unlabeled sAPPα-specific b- and y- product ions
from a CHO media standard sample. The retention time of the quadruply charged
unlabeled (PGSGLTNIKTEEVKMDAEFR of m/z = 638.98) and labeled
(PGSGL*TNIKTEEVKMDAEFR of m/z = 640.48) sAPPα peptide was approximately 25.1
min.
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Figure 4.7. Chromatography elution profiles of labeled and unlabeled sAPPα and sAPPβ
tryptic peptides as seen by peaks from a human CSF sample. sAPPα unlabeled and labeled
peptides elute from the HPLC column simultaneously (forefront), and approximately 90
sec later than the elution of sAPPβ unlabeled and labeled peptides (background). This
demonstrates that the two sAPP isoforms eluted from the HPLC column with a temporal
separation long enough for the accurate detection of both isoforms in the same exact
sample, following only one antibody-based immunoprecipitation protocol and one LC-MS
run.
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Figure 4.8. Mass spectra of labeled (forefront) and unlabeled (background) sAPPβ-specific
b- and y- product ions from a human CSF sample. The retention time of the triply charged
unlabeled (PGSGLTNIKTEEVKM of m/z = 645.41) and labeled (PGSGL*TNIKTEEVKM
of m/z = 647.41) sAPPβ peptide was approximately 29.6 min.

Figure 4.9. Mass spectra of labeled (forefront) and unlabeled (background) sAPPα-specific
b- and y- product ions from a human CSF sample. The retention time of the quadruply
charged unlabeled (PGSGLTNIKTEEVKMDAEFR of m/z = 638.98) and labeled
(PGSGL*TNIKTEEVKMDAEFR of m/z = 640.48) sAPPα peptide was approximately 31.5
min.
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Based on our computer program, SILTmass, calculations of the labeled/unlabeled b- and y- ions
for sAPPβ and sAPPα, we generated standard curves and 36 h time courses for one participant
for each sAPP species (Figure 4.10-4.13). The human 36 h time course was not optimal, but it
was the best that we were able to generate on the LTQ mass spectrometer, which was not the
most favorable instrument for quantitation because it was not sensitive enough to detect minute
changes in labeling.

Figure 4.10. Linear sAPPβ-specific standard curve, using media from CHO cells. The %
labeled/% unlabeled sAPPβ was determined by taking the ratio all the b- and y- product
ion intensities from the labeled and unlabeled peptides (see Figure 4.3.) found in media
13
with C6-leucine label at 0%, 1.25%, 2.5%, 5%, 10%, and 20%. The ratio was computed
using a custom Microsoft Excel spreadsheet with macros. This representative sAPPβ
2
standard curve indicated a high slope (m = 0.84) and high accuracy and linearity (r =
0.997). The y-intercept was slightly high (0, 0.007) which may be explained, in part, by the
natural abundance of labeled leucine in the environment and partly by noisy signal at the
lower end of standard curve.
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Figure 4.11. Linear sAPPα-specific standard curve, using media from CHO cells. The %
labeled/% unlabeled sAPPα was determined by taking the ratio of all the b- and y- product
ion intensities from the labeled and unlabeled peptides (see Figure 4.5.) found in media
13
with C6-leucine label at 0%, 1.25%, 2.5%, 5%, 10%, and 20% . The ratio was computed
using a custom Microsoft Excel spreadsheet with macros. This representative sAPPα
2
standard curve indicated a high slope (m = 0.76) and high linearity (r = 0.996). The yintercept was high (0, 0.02) which indicates a difficulty of the LTQ in accurately measuring
the lower end of standard curve. Noisy signals in the MS spectra of those standards
produced deceptively higher percentage label of peptide in those samples.
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Figure 4.12. A human CSF labeling curve for sAPPβ. The % labeled/% unlabeled sAPPβ
was determined by taking the ratio of all of the b- and y- product ion intensities from the
labeled and unlabeled peptides (see Figure 4.8.) found in CSF (collected from 0 to 36 h) of
one human participant. The ratio was computed using a custom Microsoft Excel
spreadsheet with macros. This human sAPPβ labeling curve was too noisy to produce
quantifiable results. Fractional synthesis rate and fractional clearance rate could not be
accurately determined from this data.

72

Figure 4.13. A human CSF labeling curve for sAPPα. The % labeled/% unlabeled sAPPα
was determined by taking the ratio of all of the b- and y- product ion intensities from the
labeled and unlabeled peptides (see Figure 4.9.) found in CSF (collected from 0 to 36 h) of
one human participant. The ratio was computed using a custom Microsoft Excel
spreadsheet with macros. This human sAPPα labeling curve had extremely high
background (CSF collected at t = 1 h already showed labeling at 3.25%) and was too noisy
to produce quantifiable results. Fractional synthesis rate and fractional clearance rate
could not be accurately determined from this data.

Discussion
Unfortunately, we were unable to determine turnover rates for the individual sAPP metabolites
using the above methods, because of the mass spectrometer’s lack of sufficient sensitivity. Even
though analysis of media samples produced linear standard curves, there was difficulty
producing a robust labeling CSF curve. In the CSF samples, the signal strengths of the peptides
of interest containing labeled leucine were close to the noise measurements. This was likely due
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in part to the length of our measured peptides (sAPPβ=15 amino acids; sAPPα=20 amino acids).
Peptides with much shorter amino acid sequences would be more favorable for more consistent
fragmentation using an LTQ. A more consistent fragmentation would, in turn, produce higher
signal strength for labeled and unlabeled peptides. Unfortunately the peptides following 8E5 IP
and protease digestion that we detected with the LTQ were long. The most optimal peptides for
signal strength were the peptides discussed in this chapter.
In order to find better peptides we developed a method for simultaneously measuring sAPPα and
sAPPβ from a single CSF sample following serial immunoprecipitation. This method was
developed in a non-human primate model and is outlined in the following chapter (5). It may
now be used to translate into human studies where it could help determine if and by how much βsecretase activity is altered in AD. Future studies stemming from these results are further
explored in Chapter 6.
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Chapter 5 β-secretase inhibition on the effect of
concentrations and kinetic of sAPPα, sAPPβ, and Aβ
in rhesus macaques
Introduction
Amyloid Precursor Protein is a ubiquitous transmembrane protein involved in cell signaling,
development, and gene regulation. Compared to peripheral, non-central nervous system (CNS)
tissues, CNS APP processing demonstrates increased β-secretase activity (Irizarry et al., 2001;
Fukumoto et al., 2002) and different responses to γ-secretase modulation (Cook et al., 2010).
These fundamental differences in APP processing between the CNS and peripheral
compartments are not fully understood (Ortega et al., 2013); but may be important to inform the
design and development of Alzheimer’s disease (AD) therapeutics.
Amyloid Precursor Protein is first proteolyzed by either BACE or α-secretase generating
extracellular soluble APPβ (sAPPβ) or soluble APPα (sAPPα) respectively. Subsequent to βsecretase cleavage, C99 may be cleaved by γ-secretase producing extracellular amyloid-β (Aβ)
and the APP intracellular domain (AICD). Recent reports (Portelius et al., 2010; Cook et al.,
2010) indicate that there is an alternate pathway of a tandem α-secretase and β-secretase
cleavage of APP which results in APP metabolites such as Aβ1-15/1-16. The relationship of
physiological α-secretase to β-secretase processing in the CNS is not fully understood; although
some insights from secretase inhibition studies of these enzymes suggest that APP can be
shunted to other pathways (Mattsson et. al., 2012).
Based on these and other studies, β-secretase inhibition has been proposed to decrease the
amount of APP processed into Aβ, and shunt APP to the α-secretase pathway. The predominant
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BACE in the CNS is BACE1, located mainly in the membranes of cellular compartments such as
endosomes and the trans-Golgi Network. BACE1 may be increased approximately 2-fold in
brains (Fukumoto et al., 2002; Yang et al., 2003; Li et al., 2004), or CSF, of AD patients
(Holsinger et. al., 2004; Holsinger et al., 2006; Verheijen et al., 2006; Zetterberg et al., 2008).
Brain penetrant BACE1 inhibitors capable of lowering CNS Aβ in rodent models and in nonhuman primates (Takahashi et al., 2010; Malamas et al., 2010; Sankaranarayanan et al., 2008;
Truong et al., 2010.; Sankaranarayanan et al., 2009; Cumming, et al, 2012 Mandal et al, 2012,
Stamford, et al., 2012 ), have been identified and multiple BACE inhibitors have advanced into
early stages of human clinical trials (May et al., 2011; Egan et al., 2012, Forman et al., 2013).
In this study, we sought to determine the kinetic behavior of APP metabolites and the
relationship between the α-secretase and β-secretase pathways during BACE1 inhibition in a
non-human primate model. We utilized Stable Isotope Labeling Kinetics (SILK) in combination
with a novel high affinity, selective and centrally-active BACE inhibitor to determine the
production and turnover rates of APP metabolites. The use of labeling kinetics provides a more
sensitive determination of production changes (Bateman et al., 2009) by distinguishing the newly
generated metabolites in the cerebrospinal fluid from those that previously existed.

Methods and Experimental Design
Cisterna magna ported rhesus monkey model.
Animal use procedures in this study were reviewed and approved by the Institutional Animal
Care and Use Committee at Merck Research Laboratories at West Point. They conform to the
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources,
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National Research Council, 1996). The catheterization procedures are as described previously
(Gilberto et. al., 2003; and Cook et al. 2010).
13

C6-Leucine infusion protocol and sample collection.

At 48 h prior to administration of compound or vehicle, monkeys were restricted to a diet
consisting solely of fruits and vegetables. Their diet lacked protein until after the 12 h time-point
of the study (13 h post dosing of the BACE1 inhibitor).

13

C6-leucine infusion procedures

followed by same protocol as described previously for the low dose of leucine (Cook et. al.,
13

2010). Briefly, a 4 mg/mL C6-leucine primed bolus infusion was administered intravenously
for 10 minutes, followed by a steady infusion of 4 mg/mL/h for 12 h. Baseline CSF and blood
samples were collected at 22, 20, and 1 h prior to the onset of the 10 minute primed leucine
infusion. After the leucine bolus infusion, CSF and blood samples were collected at the
following hours post leucine administration: 2, 4, 6, 8, and 12, 15, 18, 21, 24, 27, 30, 48, 54, 57,
72, and 144. For each time-point, 1500 μL CSF and 2000 μL whole blood were collected into
low-binding polypropylene tubes (Axygen). The blood was collected on K2 EDTA BD
vacutainer tubes, spun, and 800 μL of plasma was collected and placed into Axygen tubes. CSF
and plasma samples were separated into aliquots of lesser volume (into Axygen or PK tubes) and
placed immediately on dry ice, then stored in a -70 °C freezer until transfer to various
laboratories for analyses. Prior to analyses, samples were stored in a -80 °C freezer.
β-secretase inhibitor study protocol.
The Merck β-secretase inhibitor, MBI-5, was employed in a 4-way crossover randomized design
administering one of three doses of MBI-5: 10, 30, and 125 mg/kg , or vehicle (0.4%
methylcellulose) to cisterna magna ported (CMP) rhesus monkeys (n=5 male rhesus monkeys,
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10-13 years old, 8-11.7 kg). Vehicle or MBI-5 (10, 30, or 125 mg/kg) was administered orally to
conscious rhesus monkeys 1 h prior to initiating the primed 12 h

13

C6-leucine constant infusion
13

(4 mg/kg + 4 mg/kg/h). Both CSF and plasma samples were collected as mentioned under C6leucine infusion protocol to assess the pharmacokinetics and pharmacodynamics of this
compound by quantifying MBI-5 concentrations, absolute concentrations of sAPPα, sAPPβ,
13

Aβ40, and Aβ42 (as measured by ELISA), or C6-leucine labeled sAPPα, sAPPβ, and total Aβ,
13

and free C6-leucine enrichment.

Ki or IC50,
nM*
Soluble BACE1

10  1

Soluble BACE2

12  2

Cathepsin D

2,700  600

Cathepsin E

26,600 11,000

Pepsin

~70,000

Renin

9,000
swe/lon

A40 IC50

72  5

swe/lon

A42 IC50

24 6

swe/lon

sAPP IC50

230

HEK293 APP
HEK293 APP
HEK293 APP

Table 5.1. In vitro pharmacological profile of the BACE inhibitor, MBI-5. In vitro enzyme
assays utilized purified recombinant human enzymes, except for Cathepsin D which was
purified from human liver. Data shown are mean  SEM.
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Cell Culture and Media Standards.
Human H4 neuroglioma cells stably transfected with human APP751 (H4-APPwt) (courtesy of T.
E. Golde Laboratory, UF-Gainesville) were grown in Dulbecco's Modified Eagle Medium
(DMEM) for two passages. Leucine-free DMEM was obtained and supplemented with a mixture
of labeled leucine solution so that the total final leucine concentration was the same as in
standard DMEM, with leucine levels unaltered (105 mg/L). The final media solutions had: 0%,
13

1.25%, 2.5%, 5%, 10%, or 20% C6-leucine. Labeled DMEM was supplemented with 1:50 B27 and 1% each of Penicillin-Streptomycin and Zeocin. At the third passaging of the cells, cells
were pooled and split evenly. The H4-APPwt cells were reconstituted in one of the six prepared
media solutions and cultured for 24 h to allow for sufficient incorporation of label into proteins,
such as APP. Following this incubation with labeled DMEM, the media solutions were collected
and apportioned into Axygen tubes in 1 mL aliquots and immediately frozen and stored at -80 °C
until ready to use.
Aβ, sAPPβ, and sAPPα ELISA Protocols.
The assays for CSF Aβ40, Aβ42, sAPPα, and sAPPβ measurement were described previously
(Sankaranarayanan et al., 2009, Wu et al., 2011) with some modification in dilution factor.
Briefly, CSF was diluted with 3% BSA/PBS at 1:3 for Aβ42, 1:10 for Aβ40, and 1:80 for both
sAPPβ and sAPPα. Diluted CSF (100 μL) was then used for each analyte measurement. The
concentration was calculated based on each standard curve. The absolute concentrations of total
Aβ reported herein are derived by summating the absolute concentrations measured by the two
individual Aβ ELISAs: Aβ40 and Aβ42.

79

Immunoprecipitation and digestion of sAPPβ.
Immunoprecipitation (IP) of sAPPβ from CSF was performed using a rabbit monoclonal
antibody that can specifically recognize the KM-neo-epitope of sAPPβ created following the
cleavage of APP by β-secretase. The generation and specificity characterization of the prepared
anti-sAPPβ neo-epitope antibody Mrk-61 was previously described (Wu et al. 2011; Wu et al,
2012). Mrk-61 binds exclusively with sAPPβ but not to sAPPα in both western blot and direct
immunoassay with coated each recombinant protein. The purified rabbit monoclonal anti-Mrk-61
antibody was conjugated with CNBr-activated SepharoseTM 4B beads (Amersham Biosciences,
Sweden) according to the manufacturer’s protocol. The activity of the SepharoseTM 4B
conjugated Mrk-61 antibody was evaluated in immunoprecipitation efficiency with normal
rhesus CSF following overnight beads incubation and the sAPPβ level in CSF after IP was
measured with a sensitive sAPPβ ELISA (Wu et al., 2011). The characterized Mrk-61SepharoseTM 4B beads were then reconstituted in a 50% slurry of 0.02% sodium azide in
phosphate buffered saline (PBS) and stored at 4 °C until use.
From each time-point, 500 μL of CSF, along with H4-APPwt media standards (0%, 1.25%, 2.5%,
5%, 10%, 20%), was diluted 1:1 with 500 μL PBS. Protease inhibitors (40 μg/mL aprotinin and
20 μg/mL leupeptin) (Calbiochem/EMD Millipore) were added to each sample at a volume of
10μL, followed by the addition of 50μL of Mrk-61 antibody
Samples were rotated for approximately 22 h at 4 °C. At the conclusion of the rotation, samples
were centrifuged (16,837 x g) and 925 μL of the supernatant was collected into new
polypropylene tubes and stored at 4 °C for approximately 1.5 h until ready for the sAPPα/Aβ
immunoprecipitation protocol. The Mer61-3 beads were washed three times with 25mM
ammonium bicarbonate (AmBic), with centrifugation between washes. The beads wash was
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aspirated after the final rinse and 100 μL of neat formic acid was immediately added to each
sample to elute the sAPPβ from the antibody-bead complex. Samples were left for 10 minutes at
25 °C and centrifuged. The formic acid supernatant was transferred to a new polypropylene tube
and evaporated in a rotary evaporator at 37 °C for 30 minutes. The dried samples were
reconstituted with 25 mM AmBic, and 5ng sequencing-grade Metalloendopeptidase (Lys-N)
(Seikagaku Corporation/Associates of Cape Cod Inc.) in 25 mM AmBic was added. Extracts
were digested for approximately 20 h on a shaker at 37 °C and transferred into autosampler vials.
Immunoprecipitation and digestion of sAPPα and Aβ.
Prior to study onset, a mouse monoclonal antibody W0-2 (EMD Millipore, Billerica, MA)
(directed against Aβ4-10) and a mouse monoclonal antibody HJ5.1 (Washington University in St.
Louis) (directed against Aβ13-28) were covalently bound to CNBr SepharoseTM 4B beads
according to the manufacturer’s instructions, then stored in a 50% slurry of 0.02% PBS azide at 4
°C prior to use. The sAPPα/Aβ IP protocol was optimized for maximum sAPPα/Aβ signal from
the liquid chromatography-mass spectrometer system. The above-mentioned CSF and media
standard supernatants were taken from 4 °C and put on ice. To each sample 45 μL W0-2
antibody slurry and 60 μL HJ5.1 antibody slurry were added. Samples were rotated, rinsed,
eluted, and reconstituted in the same way as with the Mer61-3 antibody.
Quantitation of peptides by liquid chromatography-mass spectrometry (LC-MS).
Peptides specific to sAPPα and sAPPβ (KYL(L*)ETPGDENEHAHFQ), and Aβ
(KL(L*)VFFAEDVGSN) were analyzed on a Thermo-Finnigan LTQ equipped with a New
Objective nanoflow ESI source. The peptides were separated by RP HPLC using an Eksigent
2D-LC nanoflow pump operating in 1D mode at a flow rate of 200 nL/min. Sample (5 μL) was
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injected onto a New Objective picofrit column packed to 12 cm with 5 μm Magic C18aq packing
material (Michrom). Mobile Phase A contained 0.1% formic acid (FA) in water and Mobile
Phase B was 0.1% FA in acetonitrile (ACN).
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Figure 5.1. Rhesus macaque APP sequence. The rhesus macaque APP sequence has
approximately 91% homology with human APP. Non-homologous regions are shown in
purple. The non-homologous amino-terminal sequence is absent in humans. The human
APP sequence begins with “MLP” at its N-terminus. The second non-homologous
sequence found in the mid-domain of APP is such in humans:
AMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERL
EAKHRERMSQVMREWEEAERQAKNLPKADKKAVI. Various regions of the APP
sequence pertinent to this study are indicated, namely the amino acid sequences that this
study’s antibodies are directed against, as well as peptides used in MS quantification. Note
that even though the sAPPα and sAPPβ MS peptide used in this study’s quantification is
located in a region non-homologous to human APP, the actual peptide’s sequence
(KYLETPGDENEHAHFQ) is conserved among species.

Free Leucine Quantitation by gas-chromatography-mass spectrometry (GC-MS).
Plasma

13

C6-leucine enrichment was determined using gas capillary gas chromatography mass

spectrometry (GC-MS; Agilent 6890N gas chromatograph and Agilent 5973N mass selective
detector) in negative chemical ionization mode as described previously (Yarasheski et al., 1992;
13

Bateman et al., 2007; Cook et al., 2010). As described in Wolfe et al. (2005), C6-leucine
enrichment was quantified as a tracer to trace ratio.
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Calculation of labeled APP metabolite ratio.
The percentage of labeled metabolite was determined by taking the ratio of b- and y- product ion
intensities from the unlabeled metabolite peptide and the labeled peptide. For Aβ, the peptide
quantified was KL(L*)VFFAEDVGSN. For sAPPα and sAPPβ, the peptide was
KYL(L*)ETPGDENEHAHFQ. Mole fraction labeled was calculated.
Calculations of fractional synthesis rate and monoexponential slope fractional clearance
rate.
For each metabolite a fractional synthesis rate (FSR) and monoexponential slope fractional
clearance rate (FCR) was quantified as previously reported (Wolfe et al., 2005). Briefly, FSR
was calculated as the slope of the labeled metabolite during 2-8 h, divided by the plasma

13

C6-

leucine enrichment which serves as the precursor pool for APP synthesis. Monoexponential
slope FCR was computed using the natural logarithm of each labeled metabolite during the
clearance phase of labeling, notably 18-30 h.
Calculations of newly generated APP metabolites and Area Under the Curve (AUC)
analysis.
Similarly to Bateman et al. (2009) calculation of newly generated APP metabolites was
performed by determining the product of the percentage of metabolite labeled at a particular
time-point (established by LC-MS) and the absolute concentration of metabolite (determined by
ELISA) at that particular time-point.
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Figure 5.2. Rhesus macaque sample processing study design. Blood and CSF are collected
from rhesus macaques for biochemical assessments. Blood is collected, and the plasma
portion is used for pharmacokinetic analysis and free labeled leucine measurements by Gas
Chromatography-Mass Spectrometry (GC-MS), to determine the leucine enrichment for
which to normalize all APP metabolite labeling curves. Cerebrospinal fluid is collected
through the cistern magna port. A portion of the CSF is used for ELISA measurements of
absolute concentrations of sAPPα, sAPPβ, Aβ40, Aβ42. The remainder of the CSF is
employed for SILK analyses by Liquid Chromatography-Mass Spectrometry (LC-MS). To
isolate the particular metabolites, a serial immunoprecipitation protocol is used. Media or
CSF is first immunoprecipitated with Mrk-61, a KM neo-epitope specific antibody against
sAPPβ. After immunoprecipitation, the supernatant is collected and immunoprecipitated a
second time with a cocktail of two antibodies: W0-2 (recognizing Aβ4-10, which is within the
sAPPα sequence) and HJ5.1 (recognizing Aβ13-28). The sAPPβ/Mrk-61 bead complex from
the first immunoprecipitation is digested by Lys-N (proteolytically cleaving the protein on
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the N-terminus of Lysine residues) and the unlabeled and labeled peptides
KYL(L*)ETPGDENEHAHFQ are quantified by LC-MS to determine percentage labeled
sAPPβ at each time point and produce an sAPPβ labeling curve. Following the completion
of the second immunoprecipitation, the sAPPα/W0-2 bead complex and the Aβ/HJ5.1 bead
complex are proteolytically cleaved by Lys-N to produce the unlabeled and labeled peptides
KYL(L*)ETPGDENEHAHFQ and KL(L*)VFFAEDVGSN, respectively. These peptides
are quantified by LC-MS to determine percentage labeled sAPPα and Aβ at each time
point and to produce sAPPα and Aβ labeling curves.

Statistical Analyses.
For each analyte, area under the curve from -1 to 57 h (AUC-1-57) was calculated using the
trapezoidal rule. This time duration was chosen due to the majority of the drug effect and
labeling occurring during this time period. To estimate the effect of each active treatment versus
vehicle, a linear mixed effects model with fixed effects for treatments and random effects for
monkeys was fit to the log (base 2) of AUC-1-57. Estimates of mean differences from vehicle
were back transformed from the log scale to yield percent differences. Exposure was measured
using the area under the concentration-time curve from 0 to 59 h. Estimation of the linear
relationship between each analyte and exposure was performed using a mixed effects model like
the one above, except with the treatment effects replaced by a slope and intercept for exposure.

Results
Macaque Aβ FSR is similar to human FSR & monoexponential slope FCR much higher
than human’s.
Turnover of sAPPα and sAPPβ was slower than Aβ in the CNS. The average kinetic curves of
sAPPα, sAPPβ, and Aβ in the vehicle-treated group were evaluated (Figure 5.3.A), comparing
parameters of the three labeling curves maximum mole fraction labeled, time to peak labeling,
and AUC-1-57 analyses. Soluble APPα achieved a maximum of 0.8 ± 0.01 mole fraction labeled,
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while sAPPβ exhibited a similar labeling maximum (0.8 ± 0.7 mole fraction labeled; p = 0.8)
(Figure 5.3.B). Amyloid-β had a significantly higher peak of mole-fraction labeled (9.7 ± 0.6%
SD) compared with both sAPPα (*p = 0.01) and sAPPβ (*p = 0.01) (Figure 5.3.B). The labeling
peak time-points for sAPPα and sAPPβ were identical (t = 16.2 ± 1.6 h (SD), p = 1.0), with the
Aβ labeling peak preceding both (t = 14.4 ± 1.3 h (SD)) without reaching statistical significance
(p = 0.07) (Figure 5.3.C). There was no difference among metabolites’ AUC-1-57 values (sAPPα
AUC-1-57 = 1.9 ± 0.3 (SD); sAPPβ AUC-1-57 = 1.9 ± 0.2 (SD); Aβ AUC-1-57 = 2.0 ± 0.3 (SD), p =
0.9) (Figure 5.3.D).
To quantify the turnover rates of the APP metabolites, FSR was calculated to estimate
production rate and monoexponential slope FCR was calculated to estimate clearance rate. By
definition, FSRs and monoexponential slope FCRs are only valid when measured in a steadystate system (Wolfe et. al., 2005), thus kinetic analyses of sAPPα, sAPPβ, and Aβ were
performed exclusively using data collected from the vehicle-treated monkeys. The mean sAPPα
FSR (3.8 ± 0.4%/h (SD)) as measured in the CSF was faster than the mean sAPPβ FSR (3.1 ±
0.5%/h (SD), *p = 0.01) (Figure 5.3.E). The mean Aβ FSR was 7.3 ± 0.9%/h (SD) (Figure
5.3.E) and was comparable to the mean human Aβ FSR (dashed line) of 7.6%/h reported
previously (Bateman et. al., 2006). The mean Aβ FSR was significantly faster than that of either
sAPPβ (***p < 0.0005) or sAPPα (**p < 0.001).
Mean FCRs for sAPPα and sAPPβ were 7.8 ± 0.7%/h (SD) and 8.3 ± 1.4%/h (SD), respectively
(Figure 5.3. F). Mean Aβ FCR was 13.0 ± 1.9%/h (SD) (Figure 5.3.F) and was approximately
twice as fast as mean human Aβ FCR (dashed line) previously reported (Bateman et. al., 2006).
The FCRs of all three metabolites were significantly different (p < 0.002) as assessed by a one-
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way repeated measures ANOVA. Aβ FCR was significantly faster than FCR of either sAPPβ
(*p < 0.02) or sAPPα (*p < 0.005). The FCRs for sAPPβ and sAPPα were not significantly
different from one another (p = 0.6).

Figure 5.3. CNS metabolism of APP metabolites in vehicle-treated rhesus monkeys. A,
13
C6-leucine labeling curve profiles of vehicle-group-averaged (n=5) sAPPα, sAPPβ, and
Aβ. B, Maximum mole fraction labeled for each metabolite was determined. Aβ reached a
significantly higher maximum labeling as compared to sAPPα (paired t-test, *p = 0.01) and
sAPPβ (paired t-test, *p = 0.01). C, The time-point at which maximum labeling occurred
was not statistically significant among metabolites. D, AUC-1-57 values for each metabolite
did not differ. E, The means of FSRs of APP metabolites were significantly different from
one another (Repeated Measures ANOVA, ***p < 0.0001). The dashed line in the Aβ
column indicates the previously reported human FSR of Aβ (7.6%/h) (Bateman et. al.,
2006). F, The mean of the monoexponential slope FCR of Aβ was significantly higher than
the monoexponential slope FCRs of both sAPPα (paired t-test, **p = 0.004) and sAPPβ
(paired t-test, *p = 0.01). There was no statistically significant difference between sAPPα
and sAPPβ monoexponential slope FCRs. The dashed line in the Aβ column indicates
previously reported human FCR of Aβ (8.3%/h) (Bateman et. al., 2006).
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BACE1 inhibitor dose-dependently decreased sAPPβ and Aβ in rhesus monkey CNS.
Labeling curves of Aβ and sAPPβ, as well as absolute concentrations of both analytes measured
by ELISA, decreased dose-dependently in the presence of a BACE1 inhibitor. Concentrations of
newly generated metabolites were calculated by taking the product of percentage labeled and
absolute concentration of a given metabolite at each time-point. Like the labeling profiles and
absolute concentrations, the newly generated Aβ and sAPPβ reflect a dose-dependent decrease in
the presence of a BACE1 inhibitor. Area under the curve for Aβ labeling for each monkey after
BACE1 inhibition were normalized to that monkey’s vehicle labeling curve and averaged. Dose
dependent decreases were seen in both SILK labeled and ELISA AUC-1-57 concentrations of
both Aβ and sAPPβ.
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Figure 5.4 Effects of a BACE1 inhibitor on SILK labeling, ELISA concentrations, and
newly generated Aβ (A-C), sAPPβ (D-F), and sAPPα (G-I) in CNS of rhesus monkeys. A,
D, G) SILK Mole fraction labeled Aβ and sAPPβ decreases dose-dependently with βsecretase inhibitor, and mole fraction labeled sAPPα indicated no difference among vehicle
and drug groups (measured by LC-MS). B, E, H) ELISA concentrations of Aβ and sAPPβ
decreased dose-dependently and absolute concentrations of sAPPα increased dosedependently with a BACE1 inhibitor (measured by ELISA). C, F, I) Newly generated Aβ
and sAPPβ decreased dose-dependently and newly generated sAPPα increased dosedependently with a BACE1 inhibitor (measured as product of LC-MS labeling and ELISA
absolute concentrations at each time-point).
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We calculated the percent difference of each analyte from vehicle to each drug treatment group.
Mean values from each MBI-5 dosage group for each analyte were compared to the mean value
of that analyte’s vehicle group. The mole fraction labeled Aβ AUC-1-57 indicated a dosedependent decrease to approximately 50% at the highest BACE1 inhibitor dose of 125 mg/kg
(Figure 5.5.A, Table 5.1.); approximately 10% of the total Aβ is labeled (see above). Area
under the curves for ELISA concentrations of Aβ normalized to vehicle showed a dosedependent response to about 33%, a greater extent than measured by SILK (Figure 5.5.B, Table
5.1.). Stable isotope labeling kinetics mole fraction labeled sAPPβ AUC-1-57 indicated a dosedependent decrease to a lesser extent than Aβ: to approximately 70% of vehicle values at the
highest BACE1 inhibitor dose (Figure 5.5.C, Table 5.1.), approximately 8% of the total sAPPβ
is labeled. Similarly to Aβ, AUC-1-57 values for absolute concentrations of sAPPβ measured by
ELISA normalized to vehicle indicated a dose-dependent decrease to a greater extent
(approximately 38% at the highest inhibitor dose) compared to SILK (Figure 5.5.D, Table 5.1.).
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Figure 5.5. Effects of BACE1 inhibition on APP metabolites’ AUC-1-57. Results are
represented as percentage change from vehicle AUC-1-57. Each line represents a particular
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monkey. A, C, E) Mole fraction labeled Aβ and sAPPβ AUC-1-57 were decreased dosedependently to a maximum of approximately 48% and 70% of vehicle at the highest dose,
respectively. Analyses of mole fraction labeled sAPPα AUC-1-57 indicated that dosing
groups did not significantly differ from the vehicle-treated group. B, D, F) AUC-1-57 values
for ELISA absolute concentrations of Aβ and sAPPβ were decreased dose-dependently to a
maximum of approximately 33% and 38% of vehicle at the highest dose, respectively.
Analyses of AUC-1-57 of ELISA absolute concentrations of sAPPα presented a dosedependent increase to approximately 131% of vehicle at the highest dose.

Dosage of BACE
Inhibitor
10 mg/kg
30 mg/kg
125 mg/kg

SILK Mole
ELISA Absolute
Fraction Labeled
Concentration
Aβ (mean, SEM)
77.8 ± 6.4 %
70.8 ± 7.0%
47.5 ± 6.2%

111 ± 12.9%
58.6 ± 12.3%
33.2 ± 8.2%

sAPPβ (mean, SEM)
10 mg/kg
30 mg/kg
125 mg/kg

84.4 ± 4.4%
78.3 ± 3.4%
69.9 ± 5.1%

88.1 ± 2.1%
63.0 ± 2.7%
38.3 ± 4.4%

sAPPα (mean, SEM)
10 mg/kg
30 mg/kg
125 mg/kg

99.6 ± 9.3%
101.0 ± 3.2%
101.5 ± 6.6%

107.8 ± 7.4%
113.8 ± 5.8%
131.4 ± 6.9%

Table 5.2. Effects of BACE1 inhibition on APP metabolites’ AUC-1-57 from SILK and
ELISA assays. Values provided represent the percentage difference of a particular
metabolite’s mean AUC-1-57 in each MBI-5 dosage group from that metabolite’s mean
AUC-1-57 in the vehicle group.
BACE1 inhibition had no effect on fraction labeled sAPPα but dose-dependently increased
total sAPPα concentrations.
The labeling curves of sAPPα for vehicle and all three BACE1 inhibitor groups indicated no
differences in sAPPα fraction labeled (repeated measures ANOVA, p = 1.0) (Figure 5.4.G).
Concentrations measured by sAPPα ELISA indicated a dose-dependent increase with BACE1
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inhibition (Figure 5.4.H). Newly generated sAPPα (the product of steady state concentration
multiplied by 0.8% fraction labeled sAPPα), demonstrated dose dependent increases, but to a
lesser degree than the observed sAPPβ decrease (Figure 5.4. I).
Stable isotope labeling kinetics mole fraction labeled sAPPα AUC-1-57 indicated a lack of
significant difference among dosage groups (Figure 5.5.E, Table 5.1.). However, AUC-1-57 for
absolute concentrations of sAPPα normalized to vehicle indicated a modest dose-dependent
increase to approximately 131% at the highest dose (Figure 5.5.F, Table 5.1.).

Discussion
This study provided further evidence that CNS production of Aβ in rhesus monkeys is similar to
human. A prior study from our group (Cook et al., 2010) demonstrated this similarity between
rhesus monkeys and human primates (Bateman et. al., 2006). To date, metabolism of other APP
fragments have not been assessed in rhesus monkeys, although Dobrowolska et al. (2008)
demonstrated that total soluble APP (sAPP) was metabolized approximately two-fold slower
than Aβ in young, healthy human participants. To our knowledge, there are no prior studies
investigating metabolism of sAPPα and sAPPβ. We report that similar to total sAPP metabolism
in humans, metabolism of sAPPα and sAPPβ in rhesus monkeys was equal to one another and
was half the rate of Aβ metabolism. This correspondence between sAPP metabolisms in both
species further indicated that rhesus non-human primates are an appropriate preclinical model for
human CNS APP processing.
Herein, we report the first SILK BACE1 inhibitor study to evaluate in vivo APP metabolite
kinetics. As expected, there was a notable and dose-dependent decrease in Aβ and sAPPβ in the
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presence of the BACE1 inhibitor, indicating the drug hit its intended target. The finding that
there was a greater percentage reduction in Aβ compared with sAPPβ in the presence of the
inhibitor was consistent with Aβ having a faster turnover rate at steady state (in the vehicletreated group). Owing to conflicting results in prior studies, it was unclear whether the kinetics
of α-secretase processing of APP to sAPPα would also be altered. In cell culture assays where
BACE inhibitors were applied to the cells, APP appeared to be shunted down the α-secretase
pathway, resulting in increased sAPPα product. This contrasts with human studies that seemed
to indicate a non-competitive relationship between the α-secretase and β-secretase APP pathways
(Lewczuk et al. 2010, Gabelle et al. 2010, Alexopolous et al. 2011, Dobrowolska, in
preparation). These in vitro studies had suggested that, pharmacological intervention may alter
normal APP processing such that decreased BACE activity diverts APP into the α-secretase
pathway, producing more sAPPα. However, the in vitro setting is quite different from a whole
organism, in which our experiments are set. We sample from a site quite distal from the initial
labeling of leucine and its incorporation into APP. Not only is APP trafficked within the cell,
but its metabolites may move through many compartments in the macaque CNS between release
into the ECF from a neuron and collection within CSF from a cisterna magna port. An in vitro
labeling experiment would not have this added dimension and might not be predictive of what
we may see in vivo. Indeed, this study does not support the in vitro studies as there is no increase
in newly generated sAPPα (SILK study) during the acute period of BACE1 inhibition used in
this study. However, there was a partial dose dependent increase in sAPPα concentration
(ELISA study) at the highest doses, but this is confounded by increases in sAPPα concentrations
in the vehicle treated group. Thus, the ELISA sAPPα results are inconclusive and the SILK
sAPPα results show no significant difference at all between dose groups. Another caveat of the
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sAPPα ELISA measures is that sAPPα did not increase to same extent that sAPPβ decreased, and
there is no rebound of sAPPβ over baseline following the resumption of BACE activity as the
drug levels fall with metabolism. Thus, a build-up of APP substrate may be degraded through
mechanisms other than traditional α-secretase cleavage activities to account for these
observations. For example, recent immunoprecipitation-studies indicate that alternative α- and
β- secretase processing may occur in vivo in the human CNS, i.e. sAPPαQ686 (sAPPα’),
sAPPαK687, sAPPβM671, and sAPPβY681 (sAPPβ’) from the APP770 splice variant (Brinkmalm et
al., 2013). Conversely, the additional APP substrate may undergo lysosomal degradation.
Measurements using SILK would not reflect APP shunted toward lysosomes. For a model and
further discussion on how the BACE1 inhibitor study in rhesus macaques may be reconciled with
the human studies discussed in Chapter 2, please refer to Chapter 6.
The isotopic labeling profiles of Aβ and sAPPβ were reduced in a dose-dependent manner with
increasing doses of BACE inhibitor, concomitant with decreased CSF concentrations of these
proteins measured by ELISA, whereas the isotopic labeling profile of sAPPα was virtually
unaltered despite a dose-dependent increase of approximately 20-30% in the ELISA
concentration AUC-1-57 in the highest dose group (Figure 5.5., Table 5.1.). This apparent
dichotomy can be explained based on simulations using a non-steady state compartmental model
(BWP, unpublished observations). BACE inhibitor was introduced at around the same time as
the tracer was administered so that the system transitioned from a steady state to a non-steady
state at the time tracer entered the system. We may presume that the production of labeled Aβ
and sAPPβ was immediately decreased in a dose-dependent manner. The newly synthesized
peptides may be transferred into pools of pre-existing CSF peptides that initially remain at basal
concentrations, since turnover of the CSF pools must occur before CSF concentrations decrease
96

in response to BACE inhibition. The decreased appearance of labeled peptides in CSF preceded
the decrease in CSF concentration, thus resulting in a dose-dependent decrease in the isotopic
enrichment profile. BACE inhibition should cause the amount of APP to increase, which leads to
increased production of sAPPα due to mass action. Thus, increasing amounts of labeled sAPPα
should appear in CSF in a dose-dependent manner. However, the concentration of CSF sAPPα
will increase concomitant with and in proportion to the increased appearance of labeled sAPPα,
and thus there is little impact on the ratio of labeled to unlabeled peptide (i.e., isotopic
enrichment). The differential sensitivity of the enrichment profiles to acute inhibition versus an
increase of peptide synthesis results because the peptides are sampled from a downstream
location (CSF) that is remote from the site of BACE activity (brain).
This study has the benefit of measuring changes in APP metabolites by two separate methods:
employing SILK and mass spectrometry, as well as measuring absolute concentrations by
ELISA. SILK is a quite robust and reliable method of quantifying de novo proteins changing
over time following a labeling pulse, whereas the ELISA assays measure the steady state
concentrations of a particular metabolite. SILK is more specific to newly generated proteins and
more sensitive to detect changes at earlier time points in a secretase inhibitor setting (Bateman et
al., 2009; Cook et al., 2010) where protein levels may border near the lower level of detection or
ELISA variance masks relatively smaller changes in concentrations.
The CNS kinetic rates of APP metabolites are an important physiologic measure that is tightly
regulated and consistent across primates in studies to date. Modulation of APP processing is a
key approach in AD therapeutic development with β-secretase inhibition being an attractive
target. This is consistent with recent strong genetic evidence of a protective factor (Jonsson et
al., 2012) in individuals with a mutation at the BACE cleavage site of APP that prevents
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development of AD. The CNS in vivo study reported here indicates that while BACE inhibition
modulated APP processing in a predictable and dose-dependent fashion, it has also provided a
novel finding into the balance of BACE and α-secretase APP processing following BACE
inhibition.
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Chapter 6 General Conclusions and Future Directions
The thesis work presented here encompasses the processing of one of the proteins central to
Alzheimer’s disease pathogenesis. This protein, APP, has been implicated in AD due to the
amyloid hypothesis which posits that AD is caused by the aberrant aggregation of Aβ, which is a
direct cleavage product of APP. The study of AD pathogenesis has been around since 1906,
when Alois Alzheimer first described this disease and since then the field has evolved greatly.
However, there are still many unanswered questions about APP processing, both physiological
and pathophysiological. This thesis work provides measures of APP amounts, processing, and
kinetics in both the human and non-human primate CNS.
In this work, I present novel sAPPα and sAPPβ diurnal rhythms that are consistent with the
hypothesis that, to some extent, there exists APP regulation of the diurnal rhythms observed in
Aβ within our study and in previous reports (Bateman et al., 2007; Kang et al., 2009; Huang et
al., 2012a; Huang et al., 2012b). Similarly to Aβ, other APP metabolites also exhibit diurnal
patterns and these patterns are diminished with age. This indicates that at least a part of the
diurnal patterns observed in Aβ is due to diurnal patterns of APP. The cause of the diurnal APP
patterns is yet to be determined. It could be due to APP transcription, translation into protein, or
trafficking of the protein in the CNS. To a lesser degree, a diurnal variation in β-secretase or γsecretase may also have some effect on Aβ diurnal rhythms. Owing to our observed positive
correlations between the sAPPα diurnal rhythm and diurnal rhythms of other APP metabolites, I
speculate that the contributions of potential β-secretase and γ-secretase diurnal variation to the
overall Aβ diurnal rhythm are minimal. The source of the diurnal regulation of Aβ is likely
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upstream of the β-secretase cleavage step since sAPPα, sAPPβ, and Aβ rhythms are similar to
the extent that we have shown in Chapter 2.
In support of other recent publications, we also present that APP metabolites correlate with one
another (Lewczuk et al., 2010; Gabelle et al., 2010; Alexopolous et al., 2011). Most notably,
sAPPα and sAPPβ correlate highly positively and indicate that the β- and α-pathways are noncompetitive in hour-to-hour dynamics under normal physiological control. It appears that
cellular APP protein is not a limiting factor in this setting and that both α-secretase and βsecretase have plenty of substrate available for cleavage. Thus, when APP protein levels
fluctuate, levels of the direct cleavage products (i.e. sAPPα and sAPPβ) fluctuate in a similar
manner to one another. To test the hypothesis that Aβ diurnal rhythms are regulated by diurnal
changes in APP, one must determine cellular APP protein levels over the time-course. Although
our current study has the benefit of showing physiological APP diurnal rhythms in the human
setting, this also limits us from examining cellular holo-APP rhythms since we do not have brain
samples corresponding to the CSF samples we used in this study. It would be beneficial to backtranslate this study into mice or rats. One robust advantage of a rodent model is that many mice
or rats may be sacrificed across a spectrum of time-points within a 24 hour period so that brains
may be harvested and concentrations of holo-APP, as well as APP metabolites may be
determined by ELISA of brain homogenate samples. In order to avoid complications of intersubject variability, one would have to normalize each animal’s APP metabolites to a reference
point, such as to the CSF protein level for that particular animal at the experiment’s onset.
Measuring holo-APP and APP metabolites in brain tissue would also remove the caveat of APP
trafficking from brain to CSF. In our human study, the point of CSF draw is quite distal from the
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site of APP cleavage. Removing the extra dimension of transport of APP from brain to the CSF
collected at the L4/L5 lumbar space would simplify the system.
Similarly to other studies, we show that taken alone, sAPPα or sAPPβ concentrations are not
highly predictive biomarkers of AD or amyloidosis. They do not segregate the AD group from
the non-AD groups. However, the ratio of these two metabolites (sAPPβ/ sAPPα) distinguished
the group exhibiting amyloidosis from the non-amyloidosis group. The ratio was elevated
significantly in the older amyloid positive group compared to the young and older non-amyloid
groups. This significantly elevated ratio is not particularly surprising as there is an observed
trend, albeit statistically insignificant, for sAPPβ to be elevated with age, and further with
amyloidosis. Inter-subject variability in absolute sAPPβ levels within subject group may make it
difficult to discern potential differences in APP processing among groups. Normalizing a
subject’s sAPPβ concentration to their sAPPα concentration from a particular time-point will
decrease this inter-subject variability within groups. An increase in ratio would be a direct
consequence of increased β-secretase activity and/or decreased APP processing through the αsecretase pathway. This is consistent with our hypothesis of a shift toward β-secretase
processing of APP in AD. Thus, the sAPPβ/ sAPPα ratio may serve as an additional index to the
currently available CSF biomarkers for AD.
We report the novel finding that human total APP and rhesus macaque sAPPα or sAPPβ turnover
rates are about twice as slow as the Aβ turnover rate. The methods I developed to measure
kinetics of sAPPα, sAPPβ, and Aβ in rhesus macaque CSF may be easily performed on human
CSF that has been serially sampled over 36 hours following labeling with 13C-leucine. Such 36
hour human CSF time-courses are currently stored in the Bateman lab at -80⁰C and may be used
for such a purpose. Performing such a study using CSF from healthy young humans, older
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healthy humans, and older humans with amyloidosis, would have high implication as it would
test the hypothesis that AD is associated with increased β-secretase activity as a cause of
increased Aβ production.
Our lab was the first to develop a method to measure CNS protein metabolism in humans by
SILK. Using this technique, we discovered that Aβ is rapidly produced and cleared in the human
CNS (Bateman et al., 2006). In a γ-secretase inhibitor study, we detected small changes in Aβ
production rates, indicating SILK is a sensitive measure of CNS protein production rates
(Bateman et al., 2009). Furthermore, we have recently demonstrated an overall impaired
clearance of Aβ (Mawuenyega et al., 2010) in Alzheimer’s disease. However, half of the
subjects have increased Aβ production, while others have decreased Aβ production, suggesting a
sub-population that over-produces Aβ. Taken together, this data is suggestive of an increase in
β-secretase activity in at least some AD participants, but to date has not been directly measured.
These results have led us to hypothesize that approximately half of AD patients over-produce Aβ
owing to increased β-secretase activity, while the other half have decreased Aβ clearance. In
order to address questions of physiological and pathophysiological β-secretase (and α-secretase)
activity, we could measure sAPPβ and sAPPα kinetics in the human CNS using the above
mentioned method that I developed in rhesus macaques. By directly measuring production rates
of sAPPβ and sAPPα, we could determine if, and by how much, β-secretase activity is increased
in AD. These results would elucidate human CNS APP physiology and pathophysiology in AD.
Further, outcomes of this study may prove useful for measuring pharmacodynamic effects of
candidate therapeutics, such as β-secretase inhibitors. β-secretase is currently a high priority
target for AD, and results of altered β-secretase activity in AD are critical for understanding AD
pathophysiology and the development of disease modifying therapeutics. In order to address our
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hypothesis, we would determine sAPPβ and sAPPα production and clearance rates in at least 24
AD and 24 age-matched control patients. sAPPβ production rate is a direct measure of βsecretase activity when controlled by sAPPα production rate. We would predict that in a control
subject, sAPPβ and sAPPα production rates would be similar (Figure 6.1.A). However, in AD
changes in β-secretase and/or α secretase activity may occur and would alter sAPPβ and/or
sAPPα production rates. One unlikely prediction is that there may be no change in β- or αsecretase activity, evidenced by no change in the production rates of sAPPβ or sAPPα (Figure
6.1.B). A more likely scenario would be that increased β-secretase activity in AD leads to
increased sAPPβ production rate with a possible decrease in the sAPPα production rate, owing to
diminishing of the total APP pool (Figure 6.1.C). A third scenario would be an increase in total
APP during disease state, which would drive the increased production of both sAPPβ and sAPPα
(Figure 6.1.D).
A

B

C

Figure 6.1. Models of changes in APP processing in AD.
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D

Based on evidence of Aβ overproduction in some AD subjects and an average increase in sAPPβ
/sAPPα ratio (Figure 2.10.A), we hypothesize that the most likely of these scenarios would be
that at least half of the AD population will have increased β-secretase activity (Figure 6.1.C).
We expect that about half of AD subjects will have increased sAPPβ production rates and have
increased CSF sAPPβ to sAPPα ratio and Aβ production rate. This increase in sAPPβ
production rates will correlate with increased Aβ production rates in AD. We also hypothesize
that sAPPα production rates will decrease, and clearance rates will remain unchanged. These
results would be important because they could help to inform about the potential cause of AD, as
well as the physiological and pathophysiological processing of APP. We predict that a subgroup
of AD subjects may be affected by overproduction of Aβ and may respond differently to
treatments such as β-secretase inhibitors compared with AD subjects with only impaired Aβ
clearance. This differential response to treatment could decrease the power of a clinical study.
However, a study such as this may provide a method to identify the subgroup of AD patients
with overproduction of Aβ via increased β-secretase activity. Further, knowing the magnitude of
increased β-secretase activity will assist in determining the correct pharmacodynamic dose for a
particular patient. Several recent drug trials have failed due to insufficient efficacy of the drug,
targeting of the wrong population, or incorrect timing of treatment. As many β-secretase
inhibitors (BSIs) are currently under development, results of such a study wouldl be highly
informative to treatment programs targeting β-secretase and may identify participants for clinical
trials of BSIs with the highest chance of success, additionally offering a way to titrate the drug
for the desired pharmacodynamic effect.
We were initially surprised when we discovered the lack of increased α-secretase production
effects of a potent β-secretase (BACE1) inhibitor on APP processing. Our data clearly indicated
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that the BACE1 inhibitor, MBI-5, dose-dependently lowered both sAPPβ and Aβ as measured
independently by ELISA and SILK methods. This indicated the expected phenomenon: MBI-5
was hitting its target by blocking β-secretase. It was inhibiting β-secretase from cleaving its
substrate, APP, thus preventing APP from being processed through the β-pathway. The
intriguing question that we sought to answer was what effect, if any, would MBI-5 have on APP
processing through the α-pathway. Prior to the BACE1 inhibitor study, and as discussed in
Chapter 2, we had generated a simplistic model of interrelated APP processing pathways due to a
common APP pool from which both the α-secretase and β-secretase gained their substrate, which
they went on to cleave through the α- or β-pathway, respectively. That model was made after the
observations from human APP processing studies we had done previously and which showed a
clear positive correlation between the two direct products of the first step of APP processing by
α-secretase (sAPPα) of β-secretase (sAPPβ). Owing to these prior observations and the
subsequent hypothetical model that we had generated, we hypothesized that if MBI-5 were a
potent β-secretase inhibitor, then the common APP pool would have surplus APP which would,
in turn, be shunted down the α-pathway. Such a shunting would result in an increase in the
direct product of APP processing by α-secretase (sAPPα), which would be detectable by the
methods we were employing. We were surprised to observe that although MBI-5 did decrease
APP processing through the β-pathway, there was absolutely no corresponding change in APP
processing through the α-pathway as measured by SILK. SILK measurements of sAPPα showed
four labeling kinetic curves (for vehicle and the three doses) that were superimposable. By
ELISA, sAPPα measurements showed increases in all four study groups, including the vehicle
group. By ELISA, the sAPPα response to MBI-5 was not dose-dependent, although the highest
dose did show a 35% increase. However, with the substantial error in these measurements, and
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the observation that there was an apparent, albeit modest, increase in sAPPα in the vehicle group,
we were skeptical whether these results were representative of a truly physiological event or
caused by the ELISA assay not being fully specific for sAPPα. These observations, taken
together with our results that found no change detected in sAPPα by the sensitive SILK method,
which has been able to detect even minor changes in APP metabolites resulting from γ-secretase
inhibition (Cook et al., 2010), sporadic AD (Mawuenyega et al., 2010), and autosomal dominant
AD (Potter et al., 2013), led us to believe that APP was not being shunted to any great degree
through the classic α-secretase pathway during BACE1 inhibition, and thus our model of APP
processing may be overly simplistic. Therefore, here we propose a more sophisticated model
which alludes to both a spatial and a temporal separation of APP processing by α-secretase and
β-secretase. This model better explains the superficially disjoint phenomena observed in the
various studies of this thesis.
First, to preface the model, I will refer to background information (for review, see Chapter 1)
that indicates APP is a transmembrane protein that is abundant throughout subcellular
compartments such as the ER, Golgi apparatus, endosomes, etc. It is also located directly in the
cellular membrane. The family of ADAM proteins which are α-secretases are also ubiquitous
transmembrane proteins located throughout the cell and α-secretase cleavage of APP is evident at
the cell surface (Sisodia 1992). Thus cleavage of APP through the α-pathway may occur in
many areas within the cell but predominantly at the cell surface, and the directly resulting sAPPα
is released into the ECF. β-secretase is a transmembrane aspartyl protease whose activity is
primarily in neural tissues (neurons) (Vassar et al., 1999), although it is found to some extent
throughout most cells and tissues (Haass et al., 1992). At the cellular level, β-secretase
predominantly localizes to endosomes and the late Golgi/TGN. It requires an acidic environment
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(pH 4.5) for optimal activity. Thus, its function is highest in the acidic subcellular compartments
of the endocytic pathway, namely the early and late endosomes, as well as in the Golgi apparatus
(Koo and Squazzo, 1994; Haass et al., 1995).
In neurons, APP that has been newly synthesized is transported by the Golgi membrane
trafficking down the axon and to secretory vesicles. The secretory vesicles move APP to the cell
surface during the secretory pathway. In the secretory vesicles and at the cell membrane, APP is
predominantly cleaved by α-secretase (Sisodia et al., 1990; Hung et al., 1993; Golde et al.,
1992), releasing primarily sAPPα into the extracellular fluid (ECF). A fraction of the APP that
has not been cleaved at the membrane can be re-internalized into endosomes. At the endosome,
largely β-secretase, and subsequently γ-secretase, may cleave APP to generate sAPPβ and Aβ,
respectively. Endosomes with these β-secretase pathway APP metabolites in the lumen may fuse
with the cell membrane and release these metabolites into the ECF. Endosomes not immediately
recycled to the membrane will be trafficked down the endocytic pathway to late endosomes.
These endosomes, in turn, may fuse with the cell membrane to release any newly generated
sAPPβ and Aβ into the ECF. Conversely, the late endosome may fuse with a lysosome and any
holo-APP or APP metabolites remaining within the endosome’s lumen will subsequently be
degraded.
Based on this complex trafficking, we have generated a schematic (Figure 6.2.) of APP
processing that would reconcile the discrepancy between the positive correlation of sAPPα and
sAPPβ in humans and the phenomenon of APP not being shunted down the α-secretase pathway
in the presence of β-secretase inhibition. There is a common starting pool of translated APP,
which is consistent with sAPPα and sAPPβ being positively correlated when measured in human
CSF. Nevertheless, α- and β-secretase mostly do not have access to concomitantly cleave this
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APP at the same location within the cell. Initially APP is trafficked through the secretory
pathway to the cell surface, where it becomes available for cleavage by α-secretase.
Subsequently, APP uncleaved by α-secretase may be reinternalized into the endocytic pathway in
which β-secretase processing occurs. Endocytosis is irreversible, thus α-secretase cleavage may
not be in equilibrium with the β-secretase cleavage. When a BACE1 inhibitor is present, levels
of sAPPβ and Aβ are markedly decreased as we observe with the rhesus macaques that had MBI5 administered. The APP that remains uncleaved isn’t readily available for α-secretase cleavage
anymore because of the irreversibility of endocytosis, and, therefore, is mostly degraded in the
lysosome. This is consistent with what we observe in the BACE1 inhibitor treated rhesus
macaques: no change in sAPPα.
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Figure 6.2. Amyloid Precursor Protein processing & trafficking schematic. APP is
translated across the membrane of the endoplasmic reticulum and trafficked into the Golgi
apparatus. In the secretory pathway, APP is transported to the cell membrane. Once at the
membrane, cleaved sAPPα metabolites are released into the extracellular fluid (ECF) from
which they may travel to the CSF and be detected by our methods. Uncleaved APP may be
re-internalized into the cell in endosomes and go through the endocytic pathway. In the
endosome, APP is predominantly cleaved by β-secretase, as endosomes have an acidic
environment, which is conducive to β-secretase activity. Endosomes may be recycled to the
cell membrane, releasing any cleaved APP products, such as sAPPβ and Aβ, into the ECF,
or they may undergo lysosomal degradation. In the latter case, any cleaved APP
metabolites, as well as uncleaved APP, is degraded.
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To determine if this model is accurate it would be necessary to conduct additional experiments of
subcellular compartmentalization and cellular APP and sAPPα which were not feasible in our
present experimental set-up. Measuring cellular holo-APP (in addition to measurements of
individual APP metabolites) would help indicate whether total APP concentrations are increasing
due to β-secretase inhibition but are not being shunted down the α-secretase pathway. Total
cellular APP measurements are only feasible if one uses brain tissue. As our measurements of
APP metabolites are done using CSF and brain tissue was not available, we could not address
this. A future study should incorporate a rodent model of 13C-leucine labeling during BACE1
inhibition. Cerebrospinal fluid or interstitial fluid (ISF) could be collected prior to harvesting the
brain at key time-points over 72 hours. Time-points would be chosen based on a test CSF
labeling curve of APP metabolites done before study onset as turnover of label will likely differ
in a rodent model from our current non-human primate model. Brain tissue homogenates and
CSF could be analyzed by ELISA and SILK for all APP metabolites and the brain homogenates
could also be analyzed for holo-APP by both methods.
Additionally, we could use slices from these brains to examine the extent of subcellular
localization of APP during BACE1 inhibition. We could probe for holo-APP, sAPPβ, Aβ,
sAPPα, and BACE1 using immunofluorescence and a FRET (fluorescence resonance energy
transfer) approach to determine co-localization of these proteins during the course of BACE1
inhibition, as well as after administration of placebo (control).
One other avenue to pursue is to determine whether a potential build-up of APP substrate may be
degraded through a mechanism other than traditional α-secretase cleavage activity. A recent
study indicated that alternative α- and β- secretase processing may occur in vivo in the human
CNS, i.e. sAPPαQ686 (sAPPα’), sAPPαK687, sAPPβM671, and sAPPβY681 (sAPPβ’) from the APP770
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splice variant (Brinkmalm et al., 2013). I would propose assessing our currently banked rhesus
macaque CSF from this study to precisely determining the contributions of individual sAPP
subspecies (sAPPα, sAPPα’, sAPPβ, and sAPPβ’) to our current “sAPPα” and “sAPPβ”
measurements. Although it is not feasible to determine the amount of these subspecies with
current immunoassay systems, it has been performed with LC-MS/MS in human CSF. We could
use a protocol similar to that outlined in Brinkmalm et al. (2013) and immunoprecipitate rhesus
macaque CSF with P2-1 antibody and digest it with trypsin or Asp-N. Peptides for each sAPP
subspecies would be separated by LC-MS/MS to determine whether, sAPPα’ is increased during
BACE1 inhibition. If that is the case, this would indicate that APP does indeed get shunted
toward a type of α-secretase processing if β-secretase processing is blocked, but our prior study
was unable to determine that because we were measuring only sAPPα (by SILK).
Overall, the studies in this thesis have added to the basic science understanding of the complex
processing of APP in vivo. We have been able to provide evidence for α- and β-secretase
processing of APP from a complex single pool model, which is consistent with positive
correlation of APP metabolites from either of these two processing pathways. However, we
present BACE1 inhibition data that would suggest β-secretase inhibition is downstream from the
majority of α-secretase processing, thus indicating that APP is not shunted down the α-secretase
pathway, but it likely degraded in lysosomes. Future experiments to verify these findings are
discussed above. Further, one could imagine setting up a similar experiment to the BACE1
inhibitor study, but instead of using a BACE1 inhibitor, administering the PKC activator phorbol
12-myristate 13-acetate (PMA) which has been shown to increase secretion of sAPPα (Caporaso
et al., 1992; Buxbaum et al., 1993). If our model is correct, such an experiment would
demonstrate not only an increase in sAPPα, but also decreases in sAPPβ and Aβ if less APP is
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being trafficked through the endocytic pathway due to overwhelming α-secretase cleavage.
Tumor necrosis factor-α-converting enzyme (TACE) is the ADAM family member attributed to
the observed PMA-stimulated APP cleavage (Buxbaum et al., 1998). Therefore, another
potential experiment could be the administration of a TACE inhibitor, i.e., tumor necrosis factorα protease inhibitor (TAPI) or IC-3, which would block the PMA-stimulated secretion of sAPPα.
We could measure the β-secretase pathway APP metabolites in this study and would expect to
see them increase if our model is correct.
The studies in this thesis have also provided important clinical implications for AD patients.
Results discussed herein support the hypothesis that Aβ diurnal rhythms are at least in part due to
APP diurnal regulation. This finding is important for future clinicians measuring APP
metabolites for diagnostic purposes. In order to maintain consistent and accurate measurements,
CSF samples should always be collected at a set time of day because hourly variations of Aβ and
sAPPβ are significant. In this thesis, I also present some evidence for a potential benefit to
adding the sAPPβ/sAPPα ratio to measures for determining AD. Lastly, the BACE1 inhibitor
study in this thesis has potentially profound implications in the clinic. MBI-5 was successful at
lowering sAPPβ and Aβ in non-human primates and could be a promising drug candidate for a
human clinical trial.
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